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Summary 
 
Transcription initiation by RNA polymerase II is finely controlled by a multitude of activators and 
regulatory factors. The Mediator complex is the central coactivator that enables a response of RNA 
polymerase II to activators and repressors. During this thesis an inducible VP16 model system was 
established, which allowed analysis of transcription initiation. Formation of the transcription 
complex at the example of the general transcription factors TFIIB and TFIIH, PC4, Mediator and 
Pol II, the recruitment of the histone acetyltransferases CBP and GCN5, polyadenylation complexes 
CPSF and CstF as well as histone modifications could be followed timely resolved by ChIP 
analysis. Further, the VP16-specific A-Med complex could be analyzed in vivo and in vitro. The 
transition from an inactive to an active A-Med complex was accompanied by the loss of MED1 and 
the Cdk8 kinase module that could be linked to phosphorylation.  
 
Interestingly, A-Med seems to be able to associate with additional transcription cofactors that have 
histone acetyltransferase (CBP) and histone methyltransferase (Dot1L) activities as well as 
polyadenylation factors (CPSF and CstF). CBP could be shown to be VP16-dependently recruited 
in vivo and to interact directly with MED25 through the ACID domain. The Dot1L specific histone 
modification (metH3K79) could be detected dependent on VP16 transcription in vivo. CPSF-1 and 
CstF-64 could be detected on the promoter together with its direct interactor PC4. Their appearance 
on the promoter correlated with the detection of mRNA from the reporter gene. Taken together, A-
Med seems to integrate activities used for histone modification, transcription and polyadenylation. 
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1 INTRODUCTION
1 Introduction
1.1 The flow of genetic information
The genome of an organism encodes for the complete set of genes, about 30.000
genes in humans [Bentley et al., 2001]. Only a subset of these genes are tran-
scribed and translated at any given time. Which subset is expressed, depends
largely on the developmental state and the environmental needs of a cell. Gene
expression is a regulated processes that is tightly controlled by a complex interplay
of regulation mechanisms. The DNA encoded gene is transcribed in the nucleus
into messenger RNA (mRNA). The mRNA is getting processed and transported
to the cytoplasm of the cell where it is translated by the ribosome (Fig.1). Any of
these steps allow for regulation of genexpression.
Figure 1: The flow of genetic information.
Transcription is the fundamental process in which the DNA encoded information
is transcribed into RNA. The enzymes responsible for this process are the RNA
polymerases. The basic transcription reaction is similar in all organisms. In eu-
caryotes, RNA polymerase II transcribes all the protein coding genes. The func-
tion of RNA polymerase II transcription machinery is orchestrated by a myriad of
regulatory proteins. Activators bind sequence specifically in the vicinity of genes
and recruit additional coactivators and transcription factors. These regulatory pro-
teins influence the activity and processivity of RNA polymerase II and thereby
regulate the expression rate of genes. These regulatory proteins can directly in-
fluence transcription by stabilizing or modifying the transcription machinery and
thus promoting RNA polymerase II from initiation to elongation. Furthermore,
these coregulatory proteins may indirectly promote transcription by chromatin
decompaction either by modification of the histone tails or by removing complete
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histones. Therefore, they generate a chromatin environment that is more compe-
tent for transcription.
As soon as transcription starts, the 5’ end of the nascent mRNA is modified by the
addition of a cap to prevent the newly synthesized mRNA from degradation by
RNases. During the transcription elongation, the coding regions (exons) as well
as the non coding regions (introns) are transcribed by the RNA polymerase II to
form pre-mRNA molecules. Cotranscriptionally, the splicing machinery starts to
remove the introns and by this forms a mature mRNA molecule. Upon reaching
the termination signal at the end of the gene, RNA polymerase II stops transcrib-
ing [Greger and Proudfoot, 1998, Proudfoot, 1989, Aranda and Proudfoot, 2001].
Recognition of the precise termination point is linked to transcription initiation
and required for efficient transcription [Birse et al., 1998, Barilla et al., 2001]. In
a concerted action of the cleavage and polyadenylation factor (CPSF) and the
cleavage stimulatory factor (CstF), the newly synthesized mRNA is cleaved and
the polyadenosinetail (polyA) is added. This newly transcribed and processed
mRNA is then exported out of the nucleus to the cytoplasm, were translation into
a new protein occurs at the ribosome.
1.1.1 Structure of protein-coding genes and their regulatory sequences
Transcription is a highly complex process, that is regulated by the interplay of
gene specific transcription factors, general transcription factors and coregulators
on the level of DNA. Many regulatory elements are known. One can discriminate
between gene-specific elements that act only on one gene and global elements that
can act on a group of genes. The gene-specific elements of class II genes contain
distal- and proximal promoter elements. Regulatory DNA sequences that are lo-
cated 5’ of the coding region may be part of the promoter (Fig.2). The proximal
promoter elements are located close to the actual start site and are called UAS
(upstream activating sequence) or URS (upstream repressing sequence) respec-
tively. Typical class II core promoter elements are the TATA box that is located
approximately -30 to -25 bp upstream of the start site and the TFIIB recognition el-
ement (BRE) located just upstream (uBRE) [Struhl, 1995] or downstream (dBRE)
[Wensheng Deng and Stefan G.E. Roberts, 2005] of the TATA box. Further com-
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monly found elements are the initiator-region (Inr) that is located around the
transcription start site [Furter-Graves and Hall, 1990] and the downstream core-
promoter element (DPE) that locates about 30 bp downstream of the initiation
site, reviewed in [Smale and Kadonaga, 2003, Lewis et al., 2005]. It is notewor-
thy that none of these elements are strictly necessary for transcription initiation
and that the combination of any of these elements is sufficient to allow basal tran-
scription. The TATA box is the binding site for TBP, the TATA binding protein.
Figure 2: Core promoter elements. This figure depicts some of the elements that
can contribute to basal transcription from a core promoter. Each of these elements
is only found in a subset of promoters. A specific promoter may contain some, all
or none of these elements.
Mutational analysis defined TATA A/T AA as the consensus sequence for the
TATA box [Chen and Struhl, 1988, Singer et al., 1990, Wobbe and Struhl, 1990].
This sequence is nearly identical in all eucaryotes and emphasizes the evolution-
ary conservation of the TBP-TATA interaction. The DPE seems to act together
with the Inr element as a binding site for the general transcription factor TFIID
(Tab.2). The TBP accessory factors (TAFs) - TAF6 and TAF9 - within the TFIID
complex proved to be critical for DPE binding and thus for recognition of TATA-
less promoters. Additionally, the DPE element also seems to work through the
positive cofactor 4 (PC4) [Lewis et al., 2005].
Distal promoter elements act from the distance and can be located several kilo-
bases (kb) away from the actual transcription start site. As an interesting feature,
these distal elements can act independently of their position and orientation. En-
hancer stimulate transcription whereas silencer repress transcription. These ele-
ments are rather poorly understood and their mode of action is under discussion.
Enhancers, like promoters, are bound by sequence specific activators that form a
6
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functional enhancosome and influences the rate of transcription.
Global elements like insulators, MARs (matrix attachment regions) and SARs
(scaffold associated regions) are only poorly understood. Insulators often form
the border between hetero- and euchromatin and therefore influence the global
chromatin structure. MARs and SARs influence the localization of larger DNA
stretches by supporting DNA loop formation through attachment to the nuclear
matrix.
1.2 Eucaryotic RNA Polymerases
Unlike bacteria and archaea that posses only one RNA polymerase, eucaryotes
posses three different RNA polymerases that are responsible for the synthesis of
the different classes of RNA. According to the elution profile, they were named
RNA polymerase I to III [Roeder and Rutter, 1969]. RNA polymerase I (Pol I)
is responsible for the synthesis of ribosomal RNA (rRNA). RNA polymerase II
(Pol II) transcribes protein coding genes into messenger RNA (mRNA) and RNA
polymerase III (Pol III) transcribes transfer RNA (tRNA) [Young, 1991]. Bio-
chemically, the RNA polymerases can be distinguished according to their sensi-
tivity for α-amanitin (Tab.1). RNA polymerase I is not sensitive to α-amanitin
whereas RNA polymerase II (stronger) and RNA polymerase III (weaker) exhibit
α-amanitin sensitivity [Roeder and Rutter, 1970].
Type Gene Transcripts α-amanitin sensitivity
Pol I class I 18S-, 5.8S, 28S-rRNA none
Pol II class II mRNA, snRNA KD= 10
-8M
Pol III class III tRNA, 5S-rRNA, snRNA KD= 10
-6M
Table 1: RNA-polymerases in the eucaryotic nucleus. Transcripts and sensitivity
to α-amanitin are indicated.
In Eucarya, Pol II is highly conserved where it contains 12 subunits (Rpb1 -
Rpb12). Several crystal structures of Pol II have been solved which includes the
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10 and 12 subunit Pol II, Pol II bound to the general transcription factors TFIIS,
TFIIB as well as Pol II with nucleotides [Cramer et al., 2001, Armache et al., 2003]
[Kettenberger et al., 2003, Kettenberger et al., 2004, Bushnell et al., 2004]
[Armache et al., 2005]. As a feature specific to eucarya, the largest subunit of
Pol II - Rpb1 - contains a C-terminal domain (CTD) which consists of 25 to
52 hepta repeats with the consensus sequence YSPTSPS [Corden, 1990], the ex-
act length depends on the organism. The CTD as a whole is essential in yeast,
it’s deletion is lethal [Nonet and Young, 1989]. The CTD consensus motif is
bound by factors that regulate transcription initiation, elongation, termination
and mRNA processing [Woychik and Hampsey, 2002, Hahn, 2004, Lima, 2005].
The phosphorylation state of CTD correlates and regulates the transcription cy-
cle [Dahmus, 1996]. Only dephosphorylated CTD is bound by Mediator dur-
ing initiation, phosphorylation breaks this interaction. Mainly the Cdk/Cyclin
pairs of TFIIH (Cdk7/CyclinH) and of Mediator (Cdk8/CyclinC) are responsi-
ble for CTD phosphorylation at Ser5 during initiation. During elongation, pTEFb
(Cdk9/CyclinT) phosphorylates the CTD preferably at Ser2 [Pinhero et al., 2004].
For transcription reinitiation, the CTD has to be dephosphorylated again. In yeast,
Fcp1, Scp1 and Ssu72 are known phosphatases that dephosphorylate the CTD
[Lin et al., 2002, Meinhart et al., 2003, Kamenski et al., 2004].
CRSP (cofactor required for Sp1), a human Mediator complex, interacts with
Pol II CTD and adopts a specific conformation that differs from free Mediator
complex [Naar et al., 2002]. Mediator function needs a CTD interaction, since
yeast Mediator can not support transcription of a CTD-less Pol II. Furthermore,
only an intact CTD allows the formation of a stable Pol II / Mediator complex
[Myers et al., 1998, Asturias et al., 1999].
1.3 Transcription factors
1.3.1 The general transcription factors
The generation of functional class II in vitro transcription systems using nuclear
extracts and subsequent fractionation of these extracts led to the identification of
the general transcription factors (GTFs), TFIIA, TFIIB, TFIID, TFIIE, TFIIF and
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TFIIH (Tab.2) [Roeder, 1996, Lee and Young, 2000]. These GTFs are required for
start-site recognition, promoter melting and early transcription elongation. They
form the minimal set of factors that are required in vitro for activated transcription
initiation from model promoters [Hampsey, 1998].
Factor Function
TFIID TBP core promoter recognition, binds to the TATA box and
bends the DNA
TAFs INR and DPE recognition
TFIIA stabilization of the TBP - DNA interaction
TFIIB recruitment of RNA polymerase II and TFIIF, deter-
mination of the transcriptional start site
TFIIF recruitment of RNA polymerase to the promoter. In-
volvement in open complex formation.
TFIIE recruitment of TFIIH, modulation of the kinase- and
helicase activity of TFIIH
TFIIH XPB 3’-5’ helicase activity for promoter melting and open
complex formation
XPD 5’-3’ helicase activity for DNA repair (nucleotide ex-
cision repair; NER)
Cdk7 phosphorylation of CTD
CycH regulation of Cdk7
Table 2: The human general transcription factors
During transcription initiation, the preinitiation complex (PIC) is formed in a step-
wise process that starts with the binding of TFIID to the TATA box. TFIID con-
sists of the TATA-box binding protein (TBP) and TBP-associated factors (TAFs)
[Tora, 2002]. TBP is required for TATA recognition and bending of the pro-
moter DNA [Kim et al., 1993a, Kim et al., 1993b]. TBP together with TAFs fa-
cilitates basal transcription. The TAFs are required for activated transcription
and for recognition of TATA-less promoters. TFIIA enhances and stabilizes the
formation of this primary complex [Geiger et al., 1996, Tan et al., 1996]. Subse-
quent binding of TFIIB, Pol II, TFIIF, TFIIE and finally TFIIH completes PIC
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formation [Van Dyke et al., 1988, Buratowski et al., 1989]. The XPB helicase of
TFIIH is essential for promoter melting and is ATP dependent. The kinase activ-
ity of the Cdk7/CyclinH pair of TFIIH phosphorylates the CTD of Pol II at Ser5
[Hengartner et al., 1998]. This phosphorylation weakens the Pol II / Mediator in-
teraction and releases Pol II in the presence of NTPs into the elongation phase
[Serizawa et al., 1993, Kim et al., 1994, Li and Kornberg, 1994].
TBP is a special case, since it is involved in transcription with all three RNA
polymerases [Hernandez, 1993]. It is a component of the SL1 complex for class
I gens, in TFIID for class II genes and in part of a TFIIIB form at class III
genes. Additionally, two more TBP containing complexes are known, the TAC
[Mitsiou and Stunnenberg, 2000] complex and B-TFIID [Pereira et al., 2001], that
can substitute for TFIID at least in vitro. BTAF1 or the yeast homolog Mot1p,
were shown to interact with TBP and to regulate TBP function dynamically on
promoters of class II genes [Pereira et al., 2003, Geisberg and Struhl, 2004]. Re-
cently, two new groups of TBP paralogs were revealed. One group comprises
the TBP-like factor (TLF) and TBP-related factor 1 and 2 (TRF1 and TRF2).
These paralogs can bind to DNA sequences different from the canonical TATA
box [Dantonel et al., 1999, Rabenstein et al., 1999] and support transcription from
TATA-less promoters [Ohbayashi et al., 2003]. The second group of paralogous
genes to TBP identified in vertebrates are called TBP2s [Veenstra et al., 2000].
Not much is known about the function of these novel genes.
TFIIB is recruited to the promoter after the binding of TBP and the TAFs. Di-
rect interactions of TFIIB with TBP and the Pol II as well as with DNA have
been reported. On the level of DNA TFIIB recognizes and binds to the BRE
[Imbalzano et al., 1994]. These interactions help to position the Pol II in the right
direction and to select the proper transcriptional start site [Buratowski et al., 1989,
Nikolov D. and S., 1995, Bushnell et al., 2004].
TFIIF binds tightly to Pol II, stabilizes the PIC and helps to suppress non-
specific DNA binding of Pol II [Conaway and Conaway, 1993]. Additionally, it
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plays an important role in elongation, by preventing the pausing of Pol II. Both
subunits of TFIIF show some sequence similarities to the σ-factor of the bacterial
transcription machinery.
TFIIE interacts directly with Pol II, TFIIF and TFIIH, which it recruits to the
PIC [Flores et al., 1989]. Additional functions of TFIIE are the stimulation of the
kinase as well as the helicase activity of TFIIH [Lee and Young, 2000]. TATA
containing promoters are dependent on TFIIE where a checkpoint function for
PIC formation was suggested.
TFIIH contains four enzymatic activities, two ATP dependent DNA helicases
[Schaeffer et al., 1993], a DNA dependent ATPase [Roy et al., 1994] and a CTD
kinase [Lu et al., 1992]. It is an essential factor in transcription as well as in nu-
cleotide excision repair (NER) [Svejstrup et al., 1995]. The ATP dependent 3’ -
5’ helicase activity of XPB is required for promoter melting [Wang et al., 1992].
The kinase domain containing the Cdk7/CyclinH pair is involved in the transition
from transcription initiation to elongation [Dvir et al., 1997].
1.3.2 Activators and coactivators
DNA bound transcription activators transmit many different signals to the tran-
scription machinery. These gene specific activators can recruit additional coac-
tivators by forming direct protein-protein interactions. Typically, a transcription
activator contains a DNA binding domain as well as one or more activation do-
mains. The DNA binding domain allows sequence specific binding to promoter
regions. Several different DNA binding domains have been characterized. A com-
mon DNA binding motif is the Zinc finger, where a Zn2+atom is coordinated by
two cysteines and two histidines (e.g. in SP1). Other DNA binding domains con-
tain a helix-loop-helix (HLH) motif (e.g. in USF) or a leucine-zipper (e.g. in
CREB, Myc). The leucine-zipper is also a dimerization motif which is formed by
a series of leucines at every seventh position of an α-helix.
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The activation domains comprise normally 30 to 100 amino acids. These do-
mains are often highly flexible in solution and form secondary structures only
upon interaction with their target proteins that can be described by an induced fit
mechanism. Activation domains are categorized according to the nature of their
amino acid sequence. Commonly found activation domains are glutamine rich
(SP1, Oct1, CREB), proline rich (SMAD4, AP-2), serine-/threonine rich (Sox-2,
Sox-4) and acidic (VP16, NFκB, E1A, GAL4, p53).
1.3.3 The viral activator VP16
A well studied activator that is commonly used as a model system for acidic
activators is the Herpes simplex virion particle protein 16 (VP16). The pro-
tein contains a N-terminal DNA binding domain (amino acids 49 - 412) and a
C-terminal activation domain (amino acids 411 - 490) [Triezenberg et al., 1988,
Cousens et al., 1989]. The crystal structure of the DNA binding domain has been
solved. It shows no preferred binding to specific DNA sequences alone but recog-
nizes target sequences of Herpes simplex virus (HSV) immediate early genes in
conjunction with Oct-1 and HCF-1[Liu et al., 1999, Babb et al., 2001]. The small
activation domain can be divided into two even smaller independent functional
subdomains termed VP16:H1 (aa 411 - 456) and VP16:H2 (aa 457 - 490) (Fig.3)
[Walker et al., 1993].
Figure 3: Schematic overview of the VP16 activation domain. Both subdomains,
H1 and H2, can function separately from each other. The functionally relevant
point mutations targeting the phenylalanines are indicated.
Under physiological conditions, the activation domain is not structured but forms
a random coil instead [Donaldson and Capone, 1992]. At low pH or under hy-
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drophobic conditions, however, helical structures could be observed. Addition-
ally, interaction of VP16 with TAF9 or PC4 converts the unstructured activation
domain into an α-helix [Shen et al., 1996, Uesugi et al., 1997, Jonker et al., 2005].
Mutational analysis revealed point-mutants in VP16:H1 and VP16:H2 that com-
promise transcription in the context of transient reporter assays as well as in
viral infection. Several phenylalanine residues in both subdomains proved to
be critical for activation of transcription (VP16:H1mt, Phe442Pro; VP16:H2mt,
Phe473/475/479Ala) [Cress and Triezenberg, 1991, Sullivan et al., 1998]. The
strong transcription activation potential of VP16 is probably due to the fact that
it interacts with many components of the transcription machinery as well as with
chromatin modifying complexes. Interactions with the VP16 activation domain
were shown for the general transcription factors TFIIA [Kobayashi et al., 1995],
TFIID [Goodrich et al., 1993], TFIIF [Zhu et al., 1994], TFIIH [Xiao et al., 1994],
the cofactor PC4 [Kretzschmar et al., 1994a], the histone acetyl-transferase CBP/-
p300 [Kraus et al., 1999, Ikeda et al., 2002] and the yeast histone acetyltransferase
complexes SAGA and NuA4 [Utley et al., 1998] and the Swi/Snif histone remod-
eling complex [Neely et al., 1999]. Furthermore, VP16 interacts with human Me-
diator through the MED17 [Ito et al., 1999] and MED25 [Mittler et al., 2003] sub-
units.
1.4 Mediator complexes
A general transcription cofactor that transmits regulatory information to the basal
transcription machinery is the large multi subunit Mediator complex that contains
22-28 subunits [Myers and Kornberg, 2000, Bjorklund and Gustafsson, 2004]
[Blazek et al., 2005, Kornberg, 2005] that binds tightly to activators as well as
Pol II and controls transcription from class II genes. By binding to Pol II, it is re-
sponsible for basal transcription [Mittler et al., 2001, Baek et al., 2002] as well as
activated transcription [Flanagan et al., 1991]. Mediator is also part of a scaffold
complex that is necessary for transcription reinitiation [Yudkovsky et al., 2000].
The Mediator contains a Cdk8/Cyclin C Kinase module that phosphorylates the
CTD of Pol II at serine 5 [Hengartner et al., 1998, Borggrefe et al., 2002]. In ad-
dition Cdk8 phosphorylates Cyclin H which stimulates the CTD phosphorylation
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activity of the TFIIH associated kinase Cdk7. Therefore, Mediator does not only
serve as an assembly platform for the transcriptional machinery but also stimulates
the transition from initiation to elongation of transcription.
Mediator complexes have first been purified from yeast S. cerevisiae. Biochem-
ical screens revealed factors that bind tightly to activators [Kelleher et al., 1990,
Berger SL., 1990] this activity was further characterized and tested in a purified
transcription system [Flanagan et al., 1991]. SRB genes were shown to associate
with the CTD of the largest subunit of Pol II [Thompson et al., 1993] and with yet
unknown proteins to form the large Mediator complex [Kim et al., 1994]. Despite
the low sequence conservation among different species, Mediator seems to be con-
served throughout evolution [Boube et al., 2002, Bourbon et al., 2004]. However,
the low conservation, the enormous size of 1-2 MDa and the complexity made
it difficult to isolate human homologs of Mediator. Using the activation domain
of the Thyroid-hormone receptor, R.G. Roeders laboratory identified the TRAP
complex [Fondell et al., 1996]. Using different purification schemes several labs
were able to purify large protein complexes that showed minor differences in
their subunit compositions (ARC/CRSP, DRIP, PC2, SMCC and TRAP). All these
complexes turned out to represent human Mediator complexes [Naar et al., 1999,
Ito et al., 1999, Naar et al., 2001, Sato et al., 2004, Blazek et al., 2005].
1.4.1 Human Mediator complexes
Biochemical screens aiming at the identification of cofactors that bind the lig-
and dependent activation function (AF2) of the thyroid- and the vitamin D re-
ceptor led to the discovery of the TRAP (thyroid hormone receptor associated
proteins) [Fondell et al., 1996] and DRIP (vitamin D receptor interacting proteins)
[Rachez et al., 1999] complexes. A Cdk8-associated complex, SMCC (Srb/Mediator
containing complex) [Gu et al., 1999] proved to be identical to the TRAP complex
[Ito et al., 1999]. From the earlier mentioned coactivator fraction
[Meisterernst et al., 1991] PC2 [Kretzschmar et al., 1994b], and the CRSP com-
plex (cofactor required for Sp1) [Ryu and Tjian, 1999] were isolated. In contrast
to TRAP/SMCC and DRIP, PC2 and CRSP lack the kinase module (comprised
of MED12, MED13, Cdk8 and CyclinC). Furthermore, affinity purification us-
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new Name S. cerevisiae (old name) H. sapiens (old name)
MED1 Med1 TRAP220
MED2 Med2 -
MED3 Pgd1/Hrs1/Med3 -
MED4 Med4 TRAP36/DRIP36
MED5 Nut1 -
MED6 Med6 hMed6/Drip33
MED7 Med7 hMed7/Drip34
MED8 Med8 Arc32
MED9 Cse2/Med9 Med25
MED10 Nut2/Med10 hNut2/hMed10
MED11 Med11 HSPC296
MED12 Srb8 TRAP230/DRIP240
MED13 Srb9 TRAP240/DRIP250
MED14 Rgr1 TRAP170/DRIP150/CRSP150
MED15 Gal11 ARC105/PCQAP
MED16 Sin4 TRAP95/DRIP92
MED17 Srb4 TRAP80/DRIP77/CRSP77
MED18 Srb5 p28b
MED19 Rox3 LCMR1
MED20 Srb2 hTRFP/p28a
MED21 Srb7 hSrb7/p21
MED22 Srb6 Med24/Surf5
MED23 - βTRAP150/DRIP130/CRSP130/hSur2
MED24 - TRAP100/DRIP100/CRSP100
MED25 - ARC92/ACID1
MED26 - ARC70/CRSP70
MED27 - TRAP37/CRSP347
MED28 - Fksg20
MED29 - Hintersex
MED30 - TRAP25
MED31 Soh1 hSoh1
Cdk8 Srb10/Ssn3/Ume5 hSrb10/CDK8
Cyclin C Srb11/Ssn8/Ume3 hSrb11/CycC
Table 3: Mediator subunit nomenclature according to [Bourbon et al., 2004].
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ing the activation domains of SREBP (sterol receptor enhancer binding protein)
and VP16 identified ARC [Naar et al., 1999] a complex that proofed to be highly
related to the DRIP complex. In conclusion, two prominent forms of human Me-
diator exists, the large forms containing the kinase module (TRAP/SMCC and
ARC/DRIP) and the smaller forms that lack the kinase module (PC2 and CRSP).
1.4.2 Organization and structural properties of Mediator
The mammalian Mediator complex contains 28 to 30 subunits [Sato et al., 2004,
Malik and Roeder, 2005a] (Fig.4). Presumably, the murine and human complex
are also organized into subcomplexes and modules similar to the yeast complex
[Dotson et al., 2000]. In yeast, genetic [Lee et al., 2000], biochemical
[Myers and Kornberg, 2000] and structural studies [Dotson et al., 2000] revealed
the modular organization of Mediator. Even though comparable data for the meta-
zoan complex is lacking, an analogous organization is most likely.
Figure 4: Subunit structure of the Mediator complex. Subunits present in most
Mediator preparation are shown in red. Subunits only loosely attached to this core
Mediator are depicted in blue. The Kinase module that is restricted in the large
Mediator forms is shown in green. (Adapted from [Malik and Roeder, 2005a])
16
1.4 Mediator complexes 1 INTRODUCTION
The “small” Mediator complexes, B-Med, PC2 and CRSP have a set of 18 to 20
subunits in common that might correspond to a central core of tightly associated
proteins [Sato et al., 2004, Malik and Roeder, 2005a]. Other proteins seem to be
less strongly associated and might contribute to important mechanistic aspects
of Mediator function. These proteins are, MED1, MED23, MED24, MED16,
MED25, MED13, MED12, Cdk8 and CyclinC. The subunits MED23, MED24
and MED16 most likely constitute a submodule, because Mediator complexes iso-
lated from mouse cell deficient of either MED23 [Stevens et al., 2002] or MED24
[Ito et al., 2002a] lack each of these subunits. The four subunits MED13, MED12,
Cdk8 and CyclinC form a genetic, functional and physically separable module
in yeast [Borggrefe et al., 2002]. This kinase module is greatly reduced in the
B-Med, PC2 and CRSP complex but present in the larger TRAP and ARC com-
plexes. Most recently, PC2 and CRSP/Med2 complexes lacking the MED1 sub-
unit could be isolated [Malik et al., 2005, Taatjes and Tjian, 2004].
There is presently no high resolution X-ray structure of the complete Media-
tor available. However, low resolution electron microscopy data show an elon-
gated overall structure for yeast, human and mouse Mediator [Dotson et al., 2000,
Taatjes et al., 2002]. Yeast Mediator unfolds upon interaction with Pol II and
adopts an elongated form that reaches around the polymerase [Asturias et al., 1999].
In this extended form of Mediator, the characteristic domains, head, middle and
tail, are clearly visible. These EM studies suggest the head and middle mod-
ule as Pol II interaction surfaces. EM analysis of the human complex together
with various activators, Pol II CTD and the kinase module [Naar et al., 2002,
Taatjes et al., 2002, Taatjes et al., 2004] showed a similar overall architecture of
human and yeast Mediator. The data reasoned for conformational changes de-
pendent on the binding of the activators, the CTD and the kinase module. The
relevance of these structural changes on transcription initiation is unclear. How-
ever, it has been speculated that they facilitate PIC assembly as well as promoter
clearance. The first high resolution data for parts of the yeast Mediator could be
obtained by X-ray crystallography of the MED7/MED21 heterodimer of the mid-
dle module [Baumli et al., 2005]. This hetero dimer forms a long helical coiled-
coil like structure that spans 110 Å in length. A hinge region leads to a change in
the position of the C-terminus of 10 Å. This movement might account for at least
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some of the different conformations observed in the EM structures.
1.4.3 Transcription regulation by Mediator
The molecular details of the regulation of RNA polymerase II transcription by
Mediator are not yet completely understood. It involves complicated interaction
network between Mediator, transcriptional activators, GTF’s, cofactors and RNA
polymerase II. A key function of Mediator is probably the recruitment of Pol II
to promoter regions. Mediator was found to be associated with Pol II in solution
[Kim et al., 1994, Meyers, 2000, Taatjes and Tjian, 2004] suggesting simultane-
ous binding to promoters [Thompson et al., 1993]. This was seen in some cases
[Hatzis, 2002, Metivier R., 2003] however in other studies Mediator binds to pro-
moters first [Cosma et al., 2001, Park et al., 2001].
Mediator stimulates basal transcription in in reconstitutes yeast systems
[Kim et al., 1994] as well as human systems [Mittler et al., 2001, Baek et al., 2002,
Wu SY., 2003]. B-Med, a small Mediator complex lacking the Cdk8 and MED16
module but containing MED26 proofed to be essential in crude systems for basal
transcription [Mittler et al., 2001]. The strong effects on transcription were fre-
quently seen with small Mediators like CRSP, PC2 and B-Med [Naar et al., 1999,
Kretzschmar et al., 1994b, Mittler et al., 2001]. These complexes have been found
to bind stronger to Pol II than large Mediator complexes [Naar et al., 2002]. In-
deed, activation could directly relate to binding to the CTD of Pol II, cleavage
of CTD does not inactivate the function of Pol II but it eliminates the basal
and the activation function of Mediator [Myers et al., 1998]. TFIIH plays a key
role in the regulation of the activity of Pol II. Mediator binds directly to TFIIH
[Sakurai H., 2000, Giot l., 2003] and the Cdk7-Cyclin H pair of TFIIH is a sub-
ject of Mediator control. Mediator activates the kinase function of Kin28 the yeast
Cdk7 homolog. Additionally, Cdk8 phosphorylates the Cyclin H and thereby in-
hibits the associated Cdk7 kinase.
Towards the question how Mediator is recruited by activators, several knock out
cell lines have been generated. The pathway involving nuclear hormone receptors
like the thyroid hormone receptor (TR) uses MED1 as direct interaction partner.
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The activation function 2 (AF2) of TR binds to the Leu rich motif (LxxLL) of the
MED1 subunit to recruit the complete complex [Ito et al., 2000]. In MED1-/-cells,
even though the complex is intact, nuclear hormone receptor functions are im-
paired. However, normal activation function is observed with other activators
like VP16 and p53, that interact with different Mediator subunits [Ge et al., 2002,
Malik et al., 2004]. MED23-/-embryonic stem cells show a defect in the function
of E1A and of Elk-1 [Boyer et al., 1999, Stevens et al., 2002]. Both of these fac-
tors were shown to bind directly to MED23, thereby recruiting Mediator to the tar-
get promoter. Similarly, the MED15 subunit is required in Xenopus embryos for
the function of SMAD2-SMAD4 and SMAD3-SMAD4 complexes in the trans-
forming growth factor-β and the nodal pathways [Kato et al., 2002]. Interac-
tions of VP16 with MED17 [Ito et al., 1999] and MED25 [Mittler et al., 2003,
Yang et al., 2004] have been demonstrated. All of these interactions lead to a
recruitment of Mediator to the target promoter and hence positioning it in the
vicinity of the PIC. They also allow for targeting of activator-specific distinct Me-
diator complexes to target promoters as well as for subtle conformational changes
in Mediator, resulting from interactions with distinct activators, that could confer
activator specific properties.
1.5 Chromatin
The DNA in a cell does not exist in a bare form, but is rather bound to small basic
proteins called histones. This nucleoprotein material is termed chromatin. There
are five types of histones H1, H2A, H2B, H3 and H4. The basic unit of chro-
matin in eucaryotes consists of 200 bp of DNA wrapped around a protein octamer
formed by H2A, H2B, H3 and H4 [Chambon, 1978, Kornberg and Lorch, 2002].
In a nucleosome, 146 bp of DNA are wrapped twice around the protein core. The
remaining DNA serves as a linker, and contributes to the flexibility of the chro-
matin fiber. In this way, the chromatin fiber forms a beads on a string structure.
The flexibility of DNA enables not only the formation of nucleosomes but also
higher-ordered structures. Nucleosomes are the first stage in the condensation of
DNA. By winding the DNA around the histone octamer, the linear length of the
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DNA gets reduced. The 200 bp of DNA with a linear length of about 68 nm are
thereby packed onto a 10 nm particle. At the next step of condensation, histone
H1 plays an important role. Histone H1 binds the linker DNA in between two nu-
cleosomes. There is only one histone H1 per nucleosome compared to two copies
of each core histone. The function of histone H1 is to bind to histone H2A and
by doing so, to tether the nucleosomes together. In the second stage of chromo-
some compaction, the nucleosomes themselves form a helical structure resulting
in a 36 nm fiber. These 36 nm fibers can then be folded into even higher-ordered
chromatin loops of about 300 nm diameter as well as in the 700 nm chromosomes.
Packing DNA into nucleosomes is relevant to gen regulation. If packed into
chromatin, DNA is no longer freely accessible for many transcription factors.
Enzymes that allow tor the regulation of DNA accessibility introduce modifi-
cations at the histones or remodel nucleosomes in an ATP dependent manner
[Strahl and Allis, 2000, Becker and Horz, 2002]. In fact, many transcription co-
factors have been identified that modify histone tails, linking histone modification
directly to transcription [Bannister and Kouzarides, 1996] Common postransla-
tional modifications are acetylation, methylation, phosphorylation and ubiquiti-
nation. For many of these modifications the precise residue that gets modified
has been determined. Genes that contain histone tail modifications are recog-
nized by different transcription cofactors, a histone-code hypothesis was proposed
[Strahl and Allis, 2000, Jenuwein and Allis, 2001]. The theory implies individual
changes and/or that specific combinations of histone modification provide bind-
ing sites for different effector proteins that translate this code into different bind-
ing platforms for transcription factors. For example, hyperacetylation of histone
H3 and H4 correlate with actively transcribed genes, whereas hypoacetylation of
these histones marks repressed genes [Eberharter and Becker, 2002]. Addition-
ally, correlations to active transcription could be made for methylation of the hi-
stone H3 at K4, K36 and K79, whereas methylation of histone H3K9 is found to
mark repressed genes [Schubeler and Turner, 2005].
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Figure 5: Distribution of histone modifications across a typical yeast gene.
(Adapted from [Schubeler and Turner, 2005]).
When assessing the genome wide distribution of modified histones in yeast, one
can show that different modifications predominate at the beginning, middle and
the end of genes. Acetylated histones peak at the beginning of genes, whereas
the distribution of methylated histones depends on the extent (mono-, di-, tri-)
of methylation and the lysine that is methylated. Histone H3K4 trimethylation
predominates at the beginning of genes and correlates with acetylation of his-
tones whereas dimethylated histone H3K4 is enriched towards the middle and the
monomethylated form is most abundant at the end of genes. Methylation of hi-
stone H3K36 is seen at the beginning of a gene and gradually increases towards
the middle. Methylation of histone H3K79 is restricted to the actual gene, and is
not found in intergenic regions [Schubeler and Turner, 2005].
1.5.1 Histone modifying enzymes
HATs and HDACs are the enzymes responsible for acetylation and deacetyla-
tion of histone tails. The histone acetyl transferases (HATs) can be grouped into
three families [Marmorstein and Roth, 2001].
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(i) The GCN5 related N-acetyl-transferases (GNAT) acetylate preferentially his-
tone H3. They contain a C-terminal Bromodomain that binds to acetylated his-
tones. Members of this family are GCN5 (yeast), Elp3 (yeast), PCAF (human)
and TFIIIC (human).
(ii) The MYST family preferentially acetylates histone H4. Members contain a
Chromodomain that binds to RNA and methylated histone tails. Examples of this
family are Sas2 (yeast), Sas3 (yeast, NuA3 complex), MOZ (human) and Tip60
(human).
(iii) The CREB binding protein (CBP/p300) not only acetylates histones, but can
also use other proteins as substrates (for example, p53, TFIIE and TFIIF). The
CBP and p300 proteins contain a central Bromodomain, several Zinc fingers and
two independent domains which can be bound by several transcriptional activa-
tors. The deletion of either CBP or p300 in mouse is lethal.
The histone deacetylases (HDACs) are counter-players of the HATs in that they
reverse the activating effect of histone acetylation. There are three classes of
HDACs.
(i) The class I HDACs comprise HDAC1 / 2 / 3 and 8. They share a highly con-
served catalytic domain and their activity is closely linked to nuclear hormone re-
ceptors. HDAC1 and HDAC2 are part of the Sin3 and the NuRD/Mi2 complexes,
respectively.
(ii) The class II HDACs comprise HDAC 4 to 7 and are poorly characterized. (iii)
The class III HDACs comprise the yeast Sir proteins and the mammalian SIRT 1
to 7 proteins. Their deacetylase function is, at least in vitro, NAD+dependent.
Histone methyltransferases (HMTs) modify histone tails at either arginine or
lysine residues. Arginines can be either mono- or di-methylated by the protein
methyltransferases (PRMT1 to 5). Lysines can be mono-, di- and tri-methylated
by the HMTs. With the exception of Dot1, all the Lysine-HMTs contain a con-
served SET domain [Feng et al., 2002]. Although the methylation of histones is
chemically stable, recently the first histone demethylase (LSD1) that removes the
methyl groups from were discovered [Shi et al., 2004, Shi et al., 2005]. The ex-
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istence of demethylases was hypothesized for a long time, because the inhibitory
function of some lysine methylations needs to be overcome in order to allow tran-
scription. Histone replacement was discussed as an alternative possibility to re-
move lysine methylation from histone tails.
ATP-dependent Chromatin remodeling complexes subject nucleosomes to
conformational remodeling in addition to the covalent modifications
[Becker and Horz, 2002]. The mobilization of nucleosomes involves the ATP de-
pendent breaking and reforming of histone-DNA contacts. To date, several differ-
ent remodeling complexes have been identified. All of these complexes contain
an ATPase subunit along with additional subunits that affect regulation, efficiency
and specificity. These chromatin remodeling complexes are divided into three
groups, depending on the ATPase activity: (i) Swi/Snf, (ii) ISWI and the (iii) Mi2
group [Becker and Horz, 2002].
1.6 EBV plasmids
The Epstein-Barr virus (EBV) is an γ-Herpesvirus, that infects mostly human B-
cells but can also infect human epithelial cells. Under normal circumstances, EBV
behaves like a harmless parasite, but it also associates with different forms of can-
cers like Hodgkin-Lymphomas or T-Cell-Lymphomas [Epstein and Kaplan, 1978,
Baumforth et al., 1999]. The Epstein-Barr virus does have a dual life cycle with
a lytic and a latent phase [Bornkamm and Hammerschmidt, 2001]. After infec-
tion, the linear genome of EBV circularizes and remains as an episome in the cell
nucleus [Hurley and Thorley-Lawson, 1988]. This episome remains stable during
the latent phase of the life cycle and is passed on to the daughter cells. The latent
replication of the EBV episome starts from the origin of replication (oriP). A pre-
requisite for replication of the EBV episome is the presence of EBNA1 that binds
to the oriP region. These two components are sufficient for specific replication of
the episome.
The EBV nuclear antigen 1 (EBNA1) is an transcription activator. It controls
together with EBNA2 the expression of its own and further latent EBV genes
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Figure 6: Structure of the viral EBNA1 protein. The C-terminal domain of
EBNA1 contains the dimerization and DNA binding domain that binds specifi-
cally to the oriP region. The N-terminal transactivation domain consists of two
arginine rich regions that are involved in the replication from the oriP region. The
arginine rich regions are separated by long but non essential gly-ala repeats.
[Bornkamm and Hammerschmidt, 2001]. The binding of EBNA1 to the oriP is
mediated by its C-terminal dimerization domain and its DNA binding domain
(Fig.6). The crystal structure of the EBNA1 DNA binding domain is known.
Binding to the oriP sequence occurs as a dimer [Rawlins et al., 1985]. To couple
the EBV episome to the host genome, EBNA1 binds with its N-terminal domain
to the host genome, connecting the two genomes [Mackey and Sugden, 1999b,
Leight and Sugden, 2000, Kapoor and Frappier, 2003]. The EBV episome remains
bound to the metaphase chromosomes during the cell cycle and ensures an evenly
distribution of the episome [Leight and Sugden, 2000].
The oriP is a 1.8 kb large DNA stretch that consists of two elements, the family of
repeats (FR-element) and the dyad symmetry (DS-elements) [Yates et al., 1984,
Yates et al., 2000] (Fig.7). The FR-element contains 20 repeats of the EBNA1
binding motive and is most important for the episomal stability of the plasmid.
The second functional element, the DS-element is approximately 1 kb away from
the FR-element. The DS-element is 120 bp in length and harbors four EBNA1
binding sites in a pairwise arrangement. The DS-element is crucial for replication.
Deletion or changes in the spacing between the EBNA1 binding sites leads to the
loss of replication [Yates et al., 2000].
Exploiting the properties of the EBV episome by combining the expression of the
EBNA1 gene and the oriP on one plasmid allows the generation of episomally
stable cell lines [Mackey and Sugden, 1999a]. The advantage of such a system is
that the generation of a stable cell line is rather quick and straight forward. Copy
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Figure 7: The latent origin of replication, oriP. OriP contains two functional ele-
ments, the family of repeats (FR element) and the dyad symmetry (SD elements).
Both elements contain EBNA1 binding sites. The FR element is important for the
episomal stability of the plasmid, the DS element is crucial for replication.
numbers are around 5 to 20 copies per cell, which is considerably less than in
transient transfection assays, resembling in this respect the situation of a chromo-
somal gene more closely. A second advantage is the assembly of nucleosomes
on this plasmids in vivo. Therefore they can also be used as a model system for
chromatin related events.
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1.7 Aims and scope of this work
The aim of this study was to gain further insight into transcription initiation me-
diated by VP16. A specific objective was the establishment of an inducible VP16
system based cell lines harboring stably replicating (EBV-)based plasmids. Most
systems used for studying transcription initiation in mammalian cells so far are
either in vitro systems or make use of endogenous genes. What was missing so
far was an abstract, conditional in vivo model system that allows to verify bio-
chemical knowledge about a defined activator in a physiological context. In vitro
systems are useful to unravel molecular processes, but they usually simplify the
situation and in an extreme situation may even lead to missinterpretations, because
of non-physiological factor concentrations. The few inducible in vivo systems ex-
ploit hormone inducible endogenous activators that can act rapidly. However in
using hormones, secondary effects have to be taken into account. The use of an
exogenous DNA binding domain together with an exogenous transactivator has
the advantage of . The aim of this study was a time-resolved analysis of the
transcription initiation process using ChIP analysis. Especially the function of
Mediator and its crosstalk to other transcription cofactors were in the focus of the
investigation. One central aspect was the characterization of the VP16 specific
MED25-containing (A-Med) complexes in vivo as well as in vitro.
A second aim was the biochemical characterization of the newly identified Medi-
ator subunit MED25. Its role in forming a functional preinitiation complex and
its molecular mode of interaction with VP16. Towards this goal first steps in un-
derstanding how activators contact Mediator on a structural level were planed in
collaboration with P. Cramer.
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2 Materials and Methods
2.1 Materials
2.1.1 Instruments
Acrylamide gel electrophoresis Amersham / Hoefer / BioRad
Agarose gel electrophoresis BioRad
Analytical balance AE 100 and 163, Mettler
Autoradiography cassette Amersham, Kodak
Centrifuges Avanti, Beckman
Multifuge 3L-R, Heraeus,
5417 / 5415R, Eppendorf
Confocal light microscope TCS SP2, Leica
Developing machine Curix60, Agfa
Electroblot, semi-dry BioRad
Geigercounter LB122, Berthold
Gel drier GD2000, Hoefer
Heatingblock Thermomixer compact, Eppen-
dorf
Homogenizer Douncer, Wheaton
Incubator WJ311, Forma Scientific
Unequip, Unitherm B6200, Her-
aeus
Instant Imager Packard
Light microscope Axiovert 25, Zeiss
PCR-Thermocycler GeneAmp 2400, Applied
pH-Meter Calimatic 760, Knick
Photometer GeneQuant Pro, Amersham
Rotors JA10, JA25-50, SW41, SW28,
Beckman
Sonifier W250 and 250-D, Branson
Ultra-centrifuges L7, L8-M, Heraeus
UV-Illuminator Bachofer
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2.1.2 Chemicals and biochemicals
Acetic acid (p.a.) Roth
Acrylamide/Bisacrylamide 30% (Rotiphorese Gel 30) Roth
Acrylamide 30% / 40% Roth
Agarose Gibco
Ammonium persulfate (APS) Merck
Ammonium sulfate Merck
Ampicillin Roth
Aprotinin Sigma
Bacto Agar Difco
Bacto Trypton Difco
Bacto Yeast Extract Difco
Benzamidine Sigma
Bisacrylamide 2% Roth
Boric acide Roth
Bradford reagent BioRad
5-Bromo-4-Chloro-3-indolyl-phosphate (BCIP) Peqlab
Bromphenol Blue Sigma
BSA Roche
Caesiumchlorid Sigma
Calciumchloride Merck
Calciumhydrogenphosphate Merck
Calciumhydroxide Merck
CHAPS Sigma
Chloroform Merck
Coomassie brilliant blue R-250 Sigma
DAPI Sigma
Deoxycholat (DOC) Sigma
Dimethylsulfoxide Sigma
Dithiothreitol (DTT) Roth
Doxycycline Sigma
DMEM medium Gibco
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dNTPs Roche
Ethanol Sigma
Ethanolamine Sigma
Ethidium bromide Sigma
Ethylendiamintetraacetate disodium salt (EDTA) Merck
Fetal calf serum (FCS) Gibco
Fish DNA Sigma
Fish gelatine Sigma
Glucose Merck
Glykogen Sigma
Glycerol Roth
Glycine Roth
Hepes Biomol
Histogel mounting medium Linaris
IGEPAL CA630 (NP-40) Sigma
IPTG Roth
Isoamyl alcohol Merck
Isopropanol Merck
Leupeptin Roche
Lithiumchlorid Sigma
Magnesiumchloride Merck
β-Mercaptoethanol Sigma
Methanol Merck
Milk powder Heirler, Roth
Mimosine Sigma
N-Laurylsarcosin Sigma
Nitro-blue-tetrazolium (NBT) Peqlab
Paraformaldehyde Roth
Penicillin-Streptomycin Invitrogen
Phenol/Chloroform Roth
Phenylmethylsulfonfluoride (PMSF) Biomol
Phorbolmyristylester (PMA) Roche
Ponceau S Sigma
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Protein G-Sepharose Amersham
Protein A-Sepharose Amersham
Radiochemicals APB
RPMI 1640 medium Gibco
Sodium azide Sigma
Sodium borate Roth
Sodium carbonate Merck
Sodium chloride Roth
Sodiumdodecylsulfate (SDS) Merck
Sodium fluoride Sigma
Sodium hydroxid Merck
Sucrose Sigma
Tetramethylethylendiamin (TEMED) Sigma
Thymidine Sigma
Trishydroxidimethyl-aminomethan (Tris; p.a.) Sigma
Triton X-100 Sigma
Trypsin-EDTA Gibco
Urea Roth
Xylene cyanole Fluka
2.1.3 Additional material
Disposable plastic material Greiner, Nunc, TPP, Falcon
Dialysing tubes (Viking, MWCO 15 kDa) Roth
ECL Western Blot Kit NEN
Film X-OMAT, BioMax Kodak
Gel Drying Kit Promega
GFX Gel Band Purification Kit Amersham
Luciferase Kit Promega
mRNA Kit Qiagen
Nitrocellulose membrane BioRad
Nucleobond AX Plasmid DNA Kit Machery & Nagel
Paramgnetic beads Promega
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RT-PCR Kit Invitrogen
Siliconized Plastic tubes Sorenson
Silver Staining Kit PlusOne, Amersham
Sterilfilter Roth
Whatman 3MM Paper Whatman
TNT Kit Promega
2.1.4 Enzymes
Calf intestine phosphatase Fermentas
Klenow Fragment Fermentas
Lysozym Sigma
Pfu Polymerase Promega
Proteinase K Roche
Restriction enzymes NEB or Fermentas
RNase A Roche
T4 DNA ligase NEB or Fermentas
T4 polynucleotide kinase NEB
Taq polymerase Fermentas
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2.2 General buffers
BCx-buffer
20 mM Tris-HCl, pH 7.3 RT
0.2mM EDTA
20% (v/v) Glycerol
x mM KCl
PBS (phosphate-buffered saline)
10x stock solution, 1 liter: Working solution:
80 g NaCl 137 mM NaCl
2 g KCl 2.7 mM KCl
11.5 g Na2HPO2•2H2O 4.3 mM Na2HPO4•2H2O
2 g KH2PO4 1.4 mM KH2PO4
TBE (Tris/borate/EDTA) electrophoresis buffer
10x stock solution, 1 liter: Working solution:
121 g Tris base 100 mM Tris
61.8 g boric acid 100 mM boric acid
40 ml 0.5 mM EDTA, pH 8.0 2 mM
TBS (Tris-buffered saline)
10x stock solution, 1 liter, adjust pH to 7.6: Working solution:
121 g Tris base 100 mM Tris-HCl, pH 7.6
87.6 g NaCl 150 mM NaCl
TGS (SDS electrophoresis buffer)
10x stock solution, 1 liter: Working solution:
30.2 g Tris base 12.5 mM Tris
144 g Glycine 192 mM Glycine
10 g SDS 0.1% SDS
TE (Tris/EDTA) buffer
10 mM Tris-HCl, pH 7.3 RT
1 mM EDTA, pH 8.0
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2.3 Cloning
2.3.1 Plasmids
Plasmid cloned
pTU10 pREP4-7x tetO-Vβ8.1-Luc this work
pML53 pEBNA-SVP-GL-EµCAG-rtTA G. Bornkam
pTU6 pTet-On Clontech
pTU7 pTRE2-Luc Clontech
pTU14 pET21b- ACID345-548 this work
pTU17 pET21b- ACID345-560 this work
pTU15 pET21b- ACID393-548 this work
pTU18 pET21b- ACID393-560 this work
pTU16 pET21b- ACID426-548 this work
pTU19 pET21b- ACID426-560 this work
pGEX-VP16 T. Stühler
pGEX-VP16H1 T. Stühler
pGEX-VP16H1mt T. Stühler
pGEX-VP16H2 T. Stühler
pGEX-VP16H2mt T. Stühler
pPHSF21 pGEX-CBP1-1098
pPHS125 pGEX-CBP1098-1710
pPHS121 pGEX-CBP1678-2441
pLB60 pCI-Flag-MED251-2189 L. Berti
pLB84 pCI-Flag-MED251-870 L. Berti
pLB96 pCI-Flag-MED25∆ACID L.Berti
pGL2-MRG5 M. Meisterernst
pPHS54 RcCMV-βGal
Table 7: Plasmids used in this work.
2.3.2 Plasmid generation
The plasmid pTU10 was cloned as follows. The parental vector pPH273 (pREP4-
Vβ8.1-Luc) was cut with the restriction enzyme XhoI for 2 hours at 37◦C. After
this time, the phosphate groups were removed by Calf Intestine Alkaline Phos-
phatase (CIAP; Fermentas MBI, Cat. No. EF0341 ) according to the manufac-
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turers protocol. The linearized vector was purified over an 1% agarose gel and
recovered using the GFX DNA and Gel Band Purification Kit (Amersham, Cat.
No. 27-9602-01). The 7x tetO insert was generated by PCR, using the primers
7xTetO_5 and n7xTetO_3 together with the pTRE2-Luc vector as template. The
~400 bp PCR product was cut with the restriction enzyme XhoI and purified over
an 1% agarose gel. Vector backbone and insert were ligated in a 1:5 molar ratio
using T4 DNA ligase (Ferments MBI, Cat. No. EL0015) according to the man-
ufacturers protocol. Positive clones verified by restriction digest with XhoI and
sequencing.
The plasmids pTU14 to pTU19 were cloned as follows. The parental vector
pET21b was linearized with the restriction enzymes NdeI and XhoI for 2 hours
at 37◦C. The linearized vector was purified over an 1% agarose gel and recovered
using the GFX columns. The inserts were generated by PCR, using the primers
CID345 and CID548 for pTU14y; primers CID345 and CID560 for pTU17; primers
CID393 and CID548 for pTU15; primers CID393 and CID560 for pTU18; primers
CID426 and CID548 for pTU16; primers CID426 and CID560 for pTU19 for all
PCR reactions, the vector pLB60 was used as a template. The ~360 to 650 bp
PCR fragments were cut by the restriction enzymes NdeI and XhoI and purified
over an 1% agarose gel and recovered using GFX columns. Vector backbone and
insert were ligated in a 1:5 molar ratio using T4 DNA ligase according to the
manufacturers protocol. Positive clones were verified by restriction digest.
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2.3.3 PCR primers
Primer Sequence Application
7xTetO_5 GCC CTT TCG TCT CGA GTT TAC cloning
n7xTetO_3 TAT CTC GAG CTC GAC CCG GGT ACC cloning
CID345 CCT GCT TCC CAT ATG AGT CTG cloning
CID393 CCC TCG GTC ATA TGC AGT CAG T cloning
CID426 CAC CAA GCT GCA TAT GTC ACT GC cloning
CID548 CAG CTT CTC GAG CTG GAC CT cloning
CID560 GCC TGC TCG AGC CCC ATT C cloning
bio-pGL2 GCA TTC TAG TTG TGG TTT GTC CAA solid phase template
Luc_bio_dw GCC GGG CCT TTC TTT ATG TT solid phase template
159_for TGC CAA CTA TAT CCA TCT GCA CC ChIP
159_rev GAG TGG TAA ACT CGA GTC TAA CT ChIP
Luc-3a TTC ATA GCT TCT GCC AAC CGA ChIP
Luc-5a AAT GGA AGA CGC CAA AAA CAT ChIP
OriP_f TGA TAC CCA GTA GTA GAG TGG ChIP
OriP_r CAG CAG GAA AAG GAC AAG CAG ChIP
TRE1 AGG CGT GTA CGG TGG GAG GCC ChIP
TRE2 AGG CTG GAT CGG TCC CGG TGT ChIP
Table 8: PCR primers used in this work.
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2.4 Cell culture
2.4.1 Cell lines
HeLa Human epithelial cell line, cervical carcinoma, adherent.
HeLa Tet-On HeLa cell line expressing the Tet-VP16 transactivator
(Clontech)
HeLa Vβ8.1 HeLa Tet-On cell line carrying the episomal plasmid
pREP4-7x tetO-Vβ8.1-Luc
HeLa CMV HeLa cell line carrying the episomal plasmid pEBNA-
SVP-GL-EµCAG-rtTA
HeLa S3 HeLa cells adapted to growth in suspension
Jurkat Human T lymphoblastoid cell line, grow in suspension
Table 9: Cell lines used in this work.
2.4.2 Growth conditions
HeLa adherent cell lines were grown in Dulbecco’s modified Eagle medium
(DMEM plus 4500 mg/ml glucose, L-Glutamine, without pyruvate. Gibco Invit-
rogen, Cat. No. 11971-025) supplemented with 10% fetal bovine serum (FCS;
Gibco Invitrogen, Cat. No. 10270-106) and 1% Penicillin-Streptomycin (Gibco
Invitrogen, Cat. No. 15140-122). The adherent cells were grown in culture dishes
ranging from 15 and 10 cm down to 6 and 12 well plates (Nunc, Cat. No. 157150,
150350, 140675, 150628) in a tissue culture incubator under 5% CO2 and at 37
◦C.
Confluent cells were detached from the plates by the aid of 0.25% trypsin and
0.2% EDTA (Gibco Invitrogen, Cat. No. 25050-014) and seeded to a new plate in
the ratio of 1:4.
HeLa S3 and Jurkat suspension cells were grown in RPMI 1640 medium, L-
Glutamine (Gibco Invitrogen, Cat. No. 21875-034), supplemented with 10% FCS
and 1% Penicillin-Streptomycin. The suspension cells were grown in 25 to 175
cm2 cell culture flasks. When the cells reached a density of 0.8-1x106 cells/ml,
they were diluted to a new concentration of 0.2-0.4 cells/ml.
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Freezing of cells (5x106 cells/aliquot) was done in 90% FCS and 10% (v/v)
dimethyl-sulfoxide (DMSO). The cells were resuspended in 1 ml aliquots and
placed into a freezing box. This box was placed at -80◦C for 24 hours to freeze
the cells. The frozen aliquot’s were stored in a liquid nitrogen tank.
Thawing of cells was done in a 37◦C water bath. The cells were resuspended
in 10 ml pre-warmed medium and transferred to the culture plate or flask.
2.4.3 Transfecting cells
Calcium phosphate transfection The day prior transfection, the adherent cells
were seeded in 6-well plates at 25% confluency. 3 µg of DNA/well was brought to
22 µl with 10 mM Tris-HCl pH 7.5 and 3 µl of a 2.5 M CaCl2were added. While
gently vortexing, 25 µl of 2x HBS added were drop wise. The 100 µl calcium
phosphate-DNA precipitate was drop wise distributed onto the cells in complete
medium. The plates were incubated over night in the incubator at 37◦C under a
5% CO2 atmosphere.
2x HBS:
for 50 ml:
50 mM HEPES 0.6 g
280 mM NaCl 0.82 g
1.5 mM Na2HPO4 10.6 mg
pH with NaOH to pH 7.05 at RT
PolyFect transfection Transfection of adherent cells with PolyFect transfection
reagent (Qiagen, Cat. No. 301105) was conducted following the manufacturers
protocol. In short, for each well of an 6-well plate, 1.5 µg DNA was diluted in
100 µl of DMEM without FCS or other additives before adding 12 µl of PolyFect
reagent. The Polyfect-DNA complexes were diluted with 600 µl of complete
Medium and distributed to the cells. The PolyFect reagent is toxic for the cells,
therefore the medium has to be changed the following day.
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2.4.4 Luciferase assay
Cells monitored in a luciferase assay were normally harvested 12 to 24 hours
after transfection or induction. The assay is sensitive enough to assay 2x 104 cells
from 12 well plates. In this case the cells were lysed on the plate in 100 µl of 1x
Lysis buffer (Promga, Passive Lysis Buffer 5x, Cat. No. E194A). The lysate was
collected in a Eppendorf tube and centrifuged at full speed for 10 minutes to clear
the lysate. 20 µl were used for the luciferase assay (Promega, Luciferase Assay
System, Cat. No. E1501).
In the case of transfected cells, a vector encoding β-Galactosidase (β-Gal) was
cotransfected to normalize for transfection efficiency. In the β-Gal assay, 20 µl of
the cell lysate were incubated together with 180 µl of substrate solution for 1 hour
at 37◦C. After this time, the absorption at 420 nm was measured in a 96 well plate
reader (BIO-TEK INSTRUMENTS INC., EL800 Universal Microplate Reader).
In the case of stable cell lines, were no vector encoding β-Galactosidase could
be cotransfected, luciferase values were normalized to total protein. For this, the
protein content of the cell lysate was determined using an Bradford assay Kit
(Bio-Rad, Protein Assay, Cat. No. 500-0006). In short, 1 µl cell lysate were
mixed with 199 µl Bradford reagent (1x) in a 96-well microtiterplate and after an
incubation time of 10 minutes the absorbance at 595 nm was determined in a plate
reader (BIO-TEK INSTRUMENTS INC., EL800 Universal Microplate Reader).
2.5 Chromatin immunoprecipitation (ChIP)
To prepare the crosslinked material used in a ChIP experiment 1x108cells were
grown in 15 cm cell culture plates, for HeLa cells this are 10 plates. To crosslink
the cells formaldehyde (Roth, Cat. No. 4979.1) was added directly into the cell
culture medium to a final concentration of 1% (0.54 ml for 20 ml medium) and
incubated for 10 minutes at RT. To ensure that the formaldehyde was distributed
evenly, the plates were put on a rocking platform. After exactly 10 minutes the
crosslinking reaction was blocked by addition of 3.5 ml 2 M Glycine (125 mM
final). The excess of formaldehyde reacts with the primary amid group of the
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Glycine and therefore quenches the crosslinking reaction. The cells were then
washed twice with ice cold PBS (see Tab.2.2). A police rubberman was used to
harvest the cells from the plates. Collect the cells in a 50 ml Falcon tube.
The cell pellets were resuspended in 10 ml sonification buffer and transfered to
a 15 ml Falcon tube. Prior to sonification, glass beads were added (Sigma, Cat.
No. 9-1145) to support mixing in the suspension. The sonification duty-cycle was
30% Output, 15s On, 45s Off for a total time of 5 minutes using a Branson 250-D
sonifier equipped with a Microtip. All the sonification was done in a ice water
bath at all time. After the sonification the efficiency of the DNA shearing was
monitored. For this a 20 µl sample was incubated with 1 µl of µg/µl of Proteinase
K (Roche, Cat. No. 3-115-828) and 2 µl SDS (10%) for 1 hour at 56◦C. The DNA
was loaded on a 1% agarose gel with the majority of the sheared DNA being in
the range of 500-750 bp. The glass beads were collected by centrifugation for 15
minutes at 3500 rpm (4◦C) in a Heraeus Multifuge 3 L-R. The supernatant was
collected in a new 15 ml Falcon tube and 100 µl 20% Sarcosyl (Sigma, N-Lauroyl-
Sarcosine, Cat. No. L-5777) together with 5,67 g CsCl (ICN Biochemicals, Cat.
No. 160041) were added. The solution was transferd to an ultracentrifugation
tube (Beckman, Cat. No. 331372) and carefully balanced. The samples were
centrifuged in an SW40 rotor at 38.000 rpm for 36-48 hours at 18◦C.
After centrifugation, the gradient was harvested by puncturing the tube at the bot-
tom and collection of 1 ml fractions. These fractions were analyzed on an agarose
gel. The first fraction contains normally only very small DNA fragment and the
last fractions mainly super crosslinked DNA, which were omitted. The other frac-
tions, usually fractions 2 to 8 were pooled and dialyzed against TE containing
5% glycerol (see Tab.2.2) for two hours, followed by buffer exchange and dialysis
over night. The dialyzed samples were centrifuged in a Heraeus Multifuge 3 L-R
for 15 minutes at 5000 rpm which cleared the lysate of precipitates. The super-
natant was incubated with 0.5 ml Protein G Sepharose beads (Amersham, Protein
G Sepharose Fast Flow, Cat. No. 17-0618-03) for 2 hours at 4◦C to avoid un-
specific binding during the immunoprecipitation reaction. To prepared the beads,
they were rinsed in water and equilibrated in PBS containing 1 mg/ml BSA. Af-
ter pre-clearing, the DNA content of each sample was measured in an Eppendorf
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BioPhotometer and aliquoted to 2 OD260 units. These aliquots were frozen in
liquid nitrogen and stored at -80◦C.
For the immunoprecipitation one aliquot together with 2-5 µg antibody and 2 µg
fish sperm DNA (Serva, Cat. No. 18580) were incubated in 1 ml 1x NET buffer
over night at 4◦C on a rotating wheel. The fish sperm DNA was resuspended in
TE and sonicated to the same size as the samples (500 - 750 bp) and was treated
to be single stranded by boiling for 10 minutes and subsequent cooling on ice.
The next day, the samples were centrifuged for 15 minutes at 13’000 rpm (4◦C)
in an Eppendorf Centrifuge 5415 R to clear the IP from possible precipitates. 40
µl Protein G or Protein A Sepharose beads (depending of the antibody) together
with 40 µg BSA (Sigma, Bovine Serum Albumin, Cat. No. A3294) were pre-
pared in a new pre lubricated Eppendorf Tube (Sorenson, Cat. No. 11720). The
cleared samples were incubated with this beads for 4 hours at 4◦C on a rotating
wheel. After this time the beads were collected by centrifugation at 500 rpm in
an Eppendorf centrifuge 5415 R at 4◦C. During the washing procedure, the sam-
ples were kept on ice. The beads were washed twice with Wash-Buffer I followed
by two washes with Wash-Buffer II (depending on the antibody, see Tab. 10) and
once with Wash-Buffer III. After two final washes with TE, the protein-DNA com-
plexes were eluted in 150 µl of TE + 1% SDS. These eluates were incubated over
night at 65◦C to reverse the crosslink. In the morning, 1 µl of 15 µg/µl of Pro-
teinase K (Roche, Cat. No. 3115 828) was added and the samples were incubated
for 1 hour at 56◦C.
The DNA was recovered by Phenol-Chloroform extraction and ethanol precipita-
tion. 150 µl of Phenol/Chlorophorm/Isoamylethanol (Roth, Roti-Phenol/C/I, Cat.
No. A156.1) were added to the samples. They were vortexed and centrifuged for
10 minutes at full speed, the aqueous upper phase was collected in a new tube.
For the ethanol precipitation 9 µl 5M NaCl (final 300 mM) and 10 µg glycogen
(Sigma, Cat. No. G-1765) together with 380 µl 100% ethanol were added and the
samples were incubated for at least 2 hours at -20◦C. After 30 minutes centrifuga-
tion at full speed (4◦C) the DNA pellet was washed with 70% cold ethanol. The
clean DNA was air dried for 15 minutes and then resuspended in 40 µl of TE.
The PCR reaction to visualize a specific DNA fragment was done according to
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standard procedures. In short, 50 µl reactions were prepared, 4 µl template was
used and the products were labeled with radioactive α-32P-dCTP (Amersham,
3000 Ci/mmol, Cat. No. AA0005). To visualize the amplicon by autoradiography
the PCR product was separated on a native 6% poly acrylamide Gel.
PCR standard reaction: Template 4 µl
10 x PCR-buffer 5 µl
MgCl2 3 µl
Primer 1 (10pmol) 1 µl
Primer 2 (10pmol) 1 µl
dNTPmix (2mM) 0.4 µl
α-32P-dCTP 0.1 µl
Taq polymerase 0.5 µl
H2O 35 µl
Reaction duty cycles: 95◦C 5 min
95◦C 0.5 min
58◦C 0.5 min
72◦C 0.5 min go to step 2, 26 repetitions
95◦C 0.5 min
58◦C 0.5 min
72◦C 5 min
4◦C pause
Native 6% poly acrylamide gel: 5 x TBE 10 ml
for 50 ml Gel40 (1:19) 8 ml
H2O 32 ml
10% APS 400 µl
TEMED 40 µl
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Sonification buffer: 50 mM Hepes pH 7.9
100 mM NaCl
1 mM EDTA
1% SDS
0.1% DOC
1 mM PMSF
10x NET buffer: 550 mM Tris pH 7.4 RT
1.5 M NaCl
50 mM EDTA
5% NP-40
Wash buffer I: 20 mM Tris pH 8 RT
150 mM NaCl
2 mM EDTA
0.1% SDS
1% Triton X-100
Wash buffer II: 20 mM Tris pH 8 RT
250 - 500 mM NaCl check antibody list for details
2 mM EDTA
detergent check antibody list for details
Wash buffer III: 10 mM Tris pH 8 RT
250 mM LiCl
1 mM EDTA
1% NP-40
1% DOC
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Antibody Ref. Provider Washing buffer II
CBP sc-369 Santa Cruz Det.I, 500 mM NaCl
GCN5 sc-6303 Santa Cruz Det.I, 500 mM NaCl
Pol II sc-899 Santa Cruz Det.II, 500 mM NaCl
TFIIB sc-225 Santa Cruz Det.I, 500 mM NaCl
TFIIH sc-292 Santa Cruz Det.I, 500 mM NaCl
TRAP220 sc-5334 Santa Cruz Det.II, 500 mM NaCl
TRAP220 sc-8998 Santa Cruz Det.II, 500 mM NaCl
TRAP150 sc-5378 Santa Cruz Det.II, 500 mM NaCl
CDK8 sc-1521 Santa Cruz Det.II, 500 mM NaCl
TRAP240 Santa Cruz Det.II, 500 mM NaCl
CRSP77 sc-12453 Santa Cruz Det.II, 500 mM NaCl
MED25 9C2 E.Kremmer Det.II, 500 mM NaCl
PC4 Euro Gentech Det.II, 500 mM NaCl
CPSF sc-17289 Santa Cruz Det.II, 500 mM NaCl
CstF-64 sc-16473 Santa Cruz Det.II, 500 mM NaCl
Ac-H4 06-866 Upstate Det.I, 500 mM NaCl
Ac-H3K9 06-942 Upstate Det.I, 500 mM NaCl
trimethyl-H3K4 07-523 Upstate Det.I, 500 mM NaCl
dimethyl H3K79 07-366 Upstate Det.I, 500 mM NaCl
Table 10: Antibodies used in ChIP. Two different detergent (Det.) mixes were
included in the Washing Buffer II: Det. I : 0.1% SDS, 1% Triton X-100; Det. II:
1% Triton X-100.
2.6 RT-PCR
HeLa Vβ8.1 cells (see. Tab.9) were grown on a 10 cm tissue culture dish to
confluency (~ 4 x 106cells). Luciferase expression was induced by addition of
1 µg doxycycline (Sigma, Cat. No. D9891) per 1 ml of culture media. Total
RNA was collected from HeLa Vβ8.1 cells using the RNAeasy Kit (Qiagen, Cat.
No. 74104) according to the manufacturers protocol. The concentration of the
eluted RNA from the spin columns was determined and 2.5 µg was used for the
reverse transcriptase (RT) reaction. The RT reaction was done using oligo dT
primers according to the manufacturers protocol, using the ThermoScript RT-PCR
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Kit (Invitrogen, Cat. No. 11146-024). Quantification of the luciferase mRNA was
done in a real-time PCR reaction using the SYBR-Green Kit (PE-Biosystems, Cat.
No. 4304886) according to the manufacturers protocol.
2.7 Solid Phase assay
The templates for the solid phase assay were generated in a standard PCR reaction.
The products were separated on a 1% agarose gel, the band running at 600 bp was
recovered by using a Gel Band Purification Kit (Amersham, Cat. No. 27-9602-01)
and the DNA concentration was determined. 18 µg of DNA template was coupled
to 600 µl paramagnetic Streptavidin beads (Promega, Streptavidin MagneSphere,
Cat. No. Z5481). 75 fmol DNA was coupled to 1 µl of beads. In short, 600 µl
beads were washed 3 times in 1 ml 0.5 SSC, once in 1 ml PBS-BSA (0.5 mg/ml)
NP-40 (0.05%) and twice in 1 ml WB-buffer. For the coupling the beads were
incubated with 18 µg DNA template in 400 µl WB-buffer for 1 hour at RT in an
Eppendorf shaker. The coupling efficiency was tested by analyzing supernatants
in 1% agarose gels. Beads can be stored at 4◦C for several days.
For the assembly reaction, 18 µl beads, corresponding to 1.35 pmol DNA tem-
plate, 200 ng Gal4-VP16, 20 µl NE corresponding to about 160 µg protein and
70 µl Tx-buffer were incubated for 60 minutes at 28◦C. After incubation, the
beads were concentrated with a magnet and washed 3 times in 200 µl Tx-buffer.
When nucleotides where added to the reaction, preinitiation complexes were pre-
assembled on the template for 50 minutes. After this time the beads were con-
centrated with a magnet and washed once with 200 µl Tx-buffer. The beads were
resuspended in 95 µl Tx-buffer and 5 µl 10 mM of the specific NTP or NTP mix
was added and the reaction was incubated for additional 10 minutes at 28◦C. The
kinase inhibitor H8 was always added for the complete reaction. After the 10 min-
utes incubation, the beads were washed twice with 200 µl Tx-buffer and the bound
proteins were eluted with 2x SDS loading buffer and separated on a SDS-PAGE
mini-gel (see 2.9.8). Specific proteins were detected by Western blot analysis (see
2.9.11).
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PCR reaction: 5 µl 10x PCR Buffer
3 µl MgCl2
1 µl forward primer
1 µl reverse primer
5 µl dNTP mix
1 µl Taq polymerase
Tm 58◦C; 26 cycles
Standard assembly reaction: 18 µl beads
20 µl NE
200 ng Gal-VP16
70 µl Tx-buffer
5 µl H2O
0.5x SSC: 75mM NaCl
7.5 mM Na3citrate•2H2O
Adjust to pH 7.0 with 1 M HCl
WB-buffer: 50 mM Tris-HCl pH 8.0 RT
2 M NaCl
0.1 mM EDTA
Tx-buffer: 25 mM Hepes-KOH pH 8.2
4 mM MgCl2
5 mM DTT
5% Glycerol
0.5 mg/ml BSA
100 mM KCl + K-Glut
2.8 Immunofluorescence
HeLa cells were used for immunofluorescence. The cells were seeded onto cov-
erslips and transfected with PolyFect as described above. The preparation of the
samples was done at room temperature. The cells were washed twice with PBS
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(see Tab.2.2) and then fixed with 3.7% of paraformaldehyde/PBS (PFA/PBS) for
10 minutes. After two washes with PBS, the rest of the PFA/PBS was quenched
with 20 mM glycine/PBS for 10 minutes. The cells were again washed twice with
PBS and permeabilized with 1% Triton X-100/PBS for 15 minutes. After two
washes in PBS, the cells were blocked with 0.2% fish gelatin/PBS (Sigma Cat.
No. G-7765) for 20 min. The actual staining was carried out in a humid cham-
ber. The humid chamber is a box containing on layer of thick Whatman paper
moisten with water and a stripe of parafilm. Onto this parafilm one spots (50-100
µl) the dilutions of the primary antibodies. The coverslips were now transferred
facedown to this humid chamber and incubated 60 minutes at 37◦C. After this
time the cells were put back to the 6-well plates for the washing, which is at least
3 times 10 minutes in PBS. Incubation of the secondary antibodies conjugated to
the fluorescent dye was done as above except that it was carried out in the dark
to prevent the dye from bleaching and the incubation time was only 30 minutes.
After three washes with PBS, one can stain the DNA by DAPI. For this staining
the cells were incubated with 1 µg/ml DAPI/PBS (SIGMA Cat. No. D9564) for
10 minutes. After a final wash (3 times with PBS), the coverslips were mounted
facedown on a microscope slide in HistoGel mounting medium (Linaris ). These
preparations can be stored for up to 4 weeks at 4◦C. The analysis of the sam-
ples was done with a Leica TCS SP2 confocal microscope. The microscope is
equipped with a 63x objective and four lasers: (1) diode laser (405 nm) to excite
DAPI, (2) Ar laser (458 nm, 488 nm and 514 nm) to excite FITC (green) and Cy3
(red), (3) He-Ne laser (543 nm) to excite Cy3 and (4) He-Ne laser (633 nm) to ex-
cite Cy5. To avoid cross-talk between the dyes, the lasers were set at an intensity
such that no cross-talk appeared or if this was not possible by taking a sequential
scan in which only one dye was excited at the time. The images were acquired
using the built-in software from Leica.
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primary antibody species producer dilution
NC2 (4G7) rat E.Kremmer 1:10
MED25 (9C2) rat E.Kremmer 1:1
Flag (M2) mouse Sigma 1:400
HA (3F10) rat E.Kremmer 1:10
secondary antibody
Cy3 anti-rat Jackson Imm. Res. 1:400
FITC anti-mouse (515-095-062) Jackson Imm. Res. 1:25 - 1:100
Texas-red anti-mouse Jackson Imm. Res. 1:25 - 1:100
Table 11: Antibodies used for Immunofluorescence
2.9 Protein chemistry
2.9.1 Immunoprecipitation (IP)
When coupling antibodies to the appropriate agarose beads (either protein A or
G coated), a final concentration of 1 mg/ml antibody on the beads is desirable
(hybridoma supernatant, ~ 50 µg/ml). The antibody is incubated with the beads
for 2 hours at room temperature on the roller. After this incubation, the beads were
washed three times with PBS and three times with 0.2 M sodium borate (pH 9.0).
The beads get resuspended in 10 beads-volumes of 0.2 M sodium borate (pH 9.0)
and 5.2 mg dimethylpimilidate (DMP) per ml is added. Beads were incubated for
30 minutes at room temperature with gentle mixing. The reaction was stopped by
washing the beads twice in 0.2 M ethanolamine (pH 8.0) followed by a 2 hours
incubation in the same solution. At the end, the beads were washed with PBS and
resuspended in PBS containing 0.02% Sodium Azide for storage at 4◦C.
For the IP, 50 µl beads were equilibrated to BC150 buffer and 250 µl of NE was
added and incubated for 4 hours to over night at 4◦C on a roller. After the incu-
bation time, the beads were washed 5 times with BC buffer containing up to 500
mM KCl. BC150 buffer was always used for the last two washes to equilibrate
the beads lower salt concentration for better SDS-PAGE analysis. All steps were
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performed at 4◦C and all buffers were supplemented with fresh DTT (1 mM), pro-
tease inhibitors (200 mM PMSF, 100 mM Benzamidine, 2 µg/ml Leupeptine and
2 µg/ml Aprotinine).
2.9.2 GST-pulldown
A way to assay direct protein protein interaction is a GST-pulldown assay. For
this assay, a GST fusion protein is immobilized on a Glutation Sepharose matrix,
serves as a bait. The putative binding partner is offered as a recombinant protein.
Binding was ultimately monitored by SDS-PAGE (see 2.9.8).
GST-fusion protein was bound to Glutation Sepharose beads as described in (see
2.9.5) and the concentration on the beads determined in an Bradford assay. Nor-
mally, 5 to 20 µg fusion protein were used for one pulldown. Recombinant protein
was added in equimolar amounts, to block unspecific binding BSA was added in
a 2 - 3 fold excess or alternatively crude E.coli lysate was used. The binding
reaction was done in 400 µl BC150 buffer (see Tab.2.2) for 90 minutes at 4◦C
on a rotating wheel. The supernatant was removed and the the beads were nor-
mally washed with 100 volumes of BC150 supplemented with 0.02% NP-40, to
apply more stringency use higher salt concentrations. Bound proteins were eluted
directly in SDS-loading buffer and analyzed on an SDS-PAGE (see 2.9.8).
2.9.3 Urea dissociation assay
The immunoprecipitation with the MED15 antibody was done as just described
(2.9.1). The IP was washed 5 times with BC150 buffer for the non urea treated
sample. In all the other cases, 1 M-, 2 M- and 3 M urea washings, the beads
were washed twice with BC150 buffer, followed by two washes of BC150 supple-
mented with the appropriate urea concentration and a final wash in BC150 buffer.
Bound protein was eluted from the beads with 50 µl of 2 x SDS-loading dye and
subjected to SDS-PAGE analysis.
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2.9.4 Recombinant protein expression and purification
Recombinant proteins were expressed in E.coli, using expression plasmids encod-
ing the desired protein in the BL21 E.coli expression strain. An overnight starter
culture was diluted to an OD600 of 0.1 into 200 ml LB medium and grown at
37◦C to an OD600 of 0.6 - 0.8 where the expression of the protein was induced by
addition of 0.5 mM IPTG. To prevent the formation of inclusion bodies and to en-
hance the expression of full length protein, the E.coli culture was shifted to 30◦C
for 2 - 6 hours. In critical situations, even lower temperature in combination with
longer expression time were applied. The cells were harvested by centrifugation
for 15 minutes at 3.500 rpm (4◦C). All the following purification steps are carried
out at 4◦C.
2.9.5 GST-Tag purification
GST-taged proteins were resuspended in 10 ml of lysis buffer and lysed by incuba-
tion with 10 mg of Lysozyme for 10 minutes and sonification. For the sonification
the microtip and an output amplitude of 30% for a total time of 2 minutes with a
repetitive cycle of 10 seconds On-time and 50 seconds Off-time was used. During
the sonification, the samples were cooled in an ice-water bath. The lysate was
cleared by centrifugation for 10 minutes at 10.000 g (4◦C). In the mean time, 200
µl of Glutathione-Sepharose 4B (Amersham, Cat. No. 17-0756-01) were washed
and equilibrated in Lysis-buffer. The lysate was incubated together with the beads
for 90 minutes at 4◦C on a rotating wheel to allow binding of the fusion protein
to the matrix. The supernatant was removed and the remaining beads were sub
sequentially washed with 100 volumes of BC2000 and BC150 buffer (for BCx
buffers see Tab.2.2). To elute the immobilized fusion proteins, they were incu-
bated for 10 minutes at 4◦C in 500 of µl elution buffer. For quality control, an
aliquot was analyzed in an Coomassie stained SDS-PAGE gel (see 2.9.8).
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Lysis buffer: 20 mM Hepes pH 7.5
100 mM KCl
1 mM EDTA
10% Glycerol
0.1% NP-40
5mM β-Mercaptoethanol
add protease inhibitors before use
Elution buffer: 25 mM Tris-HCl pH 8.2 RT
100 mM KCl
10% Glycerol
0.1% NP-40
30 mM reduced Glutathione
add protease inhibitors before use
2.9.6 His-Tag purification
The purification of 6xHis-taged proteins was conducted very similar to the purifi-
cation of GST-taged proteins. Lysis of the cells was essentially the same, except
that a different Lysis-buffer was used. The cleared lysate was added to 200 µl
washed and equilibrated TALON Metal Affinity Resin (DB Bioscience, Cat. No.
8901-2) and incubated for 90 minutes at 4◦C on a rotating wheel. The beads were
washed with 100 volumes of Lysis-buffer supplemented with 5 mM Imidazole to
reduce unspecific binding. The immobilized fusion proteins were eluted by incu-
bation for 10 minutes at 4◦C in 500 µl lysis buffer supplemented with 200 mM
Imidazole. The eluted proteins were analyzed on a Coomassie stained SDS-PAGE
gel to ensure quality (see 2.9.8).
Lysis buffer: 20 mM Tris-HCl pH 7.5 RT
500 mM NaCl
10% Glycerol
0.1% NP-40
5 mM β-Mercaptoethanol
add protease inhibitors before use
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2.9.7 In vitro Transcription and Translation (TNT)
In vitro coupled transcription and translation was used to label proteins with ra-
dioactive 35S-Methionine. These proteins were offered in GST-pulldown assays
as putative binding partners.
The Promega TNT Coupled Reticulocyte Lysate System (Promega, Cat. No.
L4611) was used and the protocol of the manufacturer was essentially followed.
In short, the following reaction was assembled and incubated at 30◦C for 90 min-
utes.
TNT Lysate 12.5 µl
TNT Reaction buffer 1 µl
T7 Polymerase 0.5 µl
aa Mixture, minus Methionine 0.5 µl
35S-Methionine 1 µl
RNasin 0.5 µl
DNA-template 1 µl
H2O 8 µl
2.9.8 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE)
Protein were separated on an SDS-PAGE using either a maxi-gel system from
Hoefer or the mini-gel system from Bio-Rad. Depending of the size of the pro-
tein, either 10, 12 or 15% gels were used. T achieve better resolution and more
efficient blotting for the bigger proteins, 170:1 acrylamide / bisacrylamide gels
were used. For electrophoresis, proteins were mixed 1:6 with 6x loading buffer,
heat denatured at 95◦C and loaded onto the gel. Proteins were separated apply-
ing a current of 30 mA for the mini-gels and 50 mA for the maxi-gels. In both
cases the running buffer was 1x TGS (see Tab.2.2). The maxi-gels were connected
to a cooling system. For molecular weight determination, unstained marker was
run in parallel (Bio-Rad, SDS-PAGE standards Low Range, Cat. No. 161-0304;
Bio-Rad, SDS-PAGE standards High Range, Cat. No. 161-0303; MBI Fermen-
tas, Protein MW Marker, Cat. No. SM0431). Following electrophoresis, proteins
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were stained with Coomassie Brilliant Blue G250, silver, or subjected to Western
blotting.
6x loading Buffer: 0.35 M Tris-HCl (pH 6.8 RT)
0.12 mg/ml Bromphenol blue
40 mM β-Mercaptoethanol
15% 12% 10 % stacking gel
GelA (Roth, Cat. No. 3037.1) 5 ml 4 ml 3.3 ml 0.85 ml
GelB (Roth, Cat. No. 3039.1) 0.43 ml 0.35 ml 0.28 ml 0.35 ml
1.5 M Tris-HCl (pH 8.8 RT) 2.5 ml 2.5 ml 2.5 ml
1 M Tris-HCl (pH 6.8 RT) 0.63 ml
H2O 1.87 ml 2.95 ml 3.72 ml 3.1 ml
10% SDS 0.1 ml 0.1 ml 0.1 ml 0.05 ml
10% APS 0.1 ml 0.1 ml 0.1 ml 0.05 ml
TEMED 10 µl 10 µl 10 µl 10 µl
Low Range High Range Protein MW Marker
Myosin 200
β-galactosidase 116 116
Phosphorylase b 97 97
Serum albumin 66 66 66
Ovalbumin 45 45 45
Lactate dehydrogenase 35
Carbonic anhydrase 31
Bsp98I 25
Trypsin inhibitor 21
β-lactoglobulin 18
Lysozyme 14 14
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2.9.9 Coomassie staining
For Coomassie staining of polyacrylamide gels, the gels were incubated with
staining solution for at least 30 minutes on an slowly rocking platform. To vi-
sualize protein bands, the gels were destained overnight in destaining solution or
in dH2O. After destaining, the gels were scanned and then dried between cello-
phane film at RT.
Coomassie staining solution: Methanol 400 ml
Glacial acetic acid 100 ml
Coomassie R-250 0.25 g
H2O 500 ml
Destaining solution: Methanol 500 ml
Glacial acetic acid 100 ml
H2O 400 ml
2.9.10 Silver staining
Silver was used as a more sensitive staining reagent using the Silver Staining-Kit
(Amersham, Cat. No. 17-1150-01) protocol. In short, the gels were fixed in 2.5
% Acetic acid and 40% Ethanol for 30 minutes. After this time the gels were
rinsed twice in dH2O. Sensitization was done with 30% Ethanol, 0.125% Glutar-
dialdehyde (w/v), 0.2% Sodium thiosulphate (w/v) for 30 minutes. The gels were
washed 4 times for 5 minutes with dH2O. The Silver reaction was done in 0.25%
Silver nitrate solution and 0.014% Formaldehyde. The gels were washed 4 times
for 1 minute with dH2O. Finally the gels were developed in Sodium carbonate
and 0.007% Formaldehyde. The reaction was stopped with EDTA-Na2•2H2O.
2.9.11 Western
Protein separated by SDS-PAGE were transfered to a nitrocellulose membrane
(Bio-Rad, Cat. No. 162-0115) using a Semi-Dry Transfer Cell (Bio-Rad, Trans-
Blot SD). For protein transfer, the gels was sandwiched between gel-sized What-
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man papers, soaked in transfer buffer and run for 30 minutes at 15 V (mini-gels) or
60 minutes at 15 V (maxi-gels). After transfer, the membrane was shortly stained
with a Ponceau S solution to make the transfered marker visible. The membrane
was then incubated for 1-12 hours in TBS containing 5% milk powder to reduce
unspecific background binding. After blocking, the membrane was incubated for
1-12 hours with appropriate dilutions of the primary antibodies in TBS-T (1x TBS,
0,05% Tween) containing 1% milk powder (see Tab.2.2). To remove excess anti-
body, the membrane was washed 3 times for 15 minutes with TBS-T. Secondary
antibodies (1:10’000 dilution) were applied for 30 minutes in TBS-T and after 3
times 15 minutes washes in TBS-T and a final rinse in dH2O the antibodies were
detected using the enhanced chemiluminescence detection system (Perkin Elmer,
Western Lightning Cat. No. NEL105) according to the manufacturer’s instruc-
tions and exposed on BioMax MR film (Kodak, Cat. No. 873 6936).
Transfer buffer: 190 mM Glycine (14.4 g)
50 mM Tris base (15 g)
0.05% SDS (0.5 g)
20% Ethanol (200 ml)
800 ml H2O
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3 Results
3.1 Transcription in an inducible VP16 system
3.1.1 Generation of a doxycycline inducible HeLa cell system
To study recruitment and crosstalk of various transcription factors upon transcrip-
tion initiation, we are in need of a system that is able to fulfill several demands.
Firstly, it has to be direct, meaning that the signal that turns the system on has to
be unique and independent of many activators. Secondly, it has to be fast, which
requires that the activator is translated before induction. Thirdly, monitoring of ac-
tivation should rely on an easy read-out like luciferase activity. Fourthly, it should
be genetically flexible, such that promoters and activators remain interchangeable.
A system based on the commercial Tet-On gene expression system meets essen-
tially all of these requirements [Gossen, 1992, Gossen, 1994]. The activator, Tet-
VP16 is readily available in the cell and upon induction with doxycycline binds
exclusively to the reporter plasmid. This reporter consists of the tetracycline-
response element (TRE). In our experimental setup, the TRE consisted of seven
direct repeats of a 42-bp sequence containing the tet operator sequence (7x tetO)
and is located just upstream of the minimal CMV promoter (CMVmin). The re-
sponse of the system is fast. Janicki et al. (2004) showed that the Tet-VP16 trans-
activator binds to the 7x tetO sites within minutes and luciferase is measurable
hours after induction [Cunningham, 1997].
A 300 bp PCR fragment containing the 7x tetO sites from the Clontec vector
pTRE2 was integrated upstream of the rearranged T-cell receptor beta promoter
Vβ8.1 (Fig.8A). The vector backbone, pRep4, is a commercially available vec-
tor from Invitrogen. This vector carries the EBV oriP and the expression cassette
for EBNA1, together that ensured the stable episomal expression of the vector.
The plasmid also carries the selection markers ampicillin (for selection in pro-
caryotes) and hygromycin (for selection in eucaryotes). The reporter plasmid was
transfected into a HeLa cell line carrying a chromosomal expression cassette for
the Tet-VP16 fusion protein (Clontech). The reporter plasmids were transfected
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Figure 8: Reporter plasmids for the inducible VP16 system. A) pREP4 based
plasmid carrying the expression cassette for the EBNA1 gene and the oriP region
(red), both originating from the Epstein-Barr virus, to ensure episomally stable
replication of the plasmid. The luciferase gene is under the regulation of the TCR
promoter Vβ8.1 and the tet responsive element 7x tetO (green). B) Related vector
with a different bidirectional CMV promoter. The minimal CMV promotes drive
expression of the luciferase as well as the GFP gene. The vector also carries a
constitutive active expression cassette for the transactivator Tet-VP16.
into HeLa cells. Transfected cells were selected for two weeks with hygromycin
to generate stable episomal cell lines.
The functionality of the reporter was tested in transient reporter assays, in which
a plasmid expressing Tet-VP16 (Tet-On; Clontech) and the newly cloned reporter
(7x tetO Vβ) were cotransfected into HeLa cells. Addition of doxycycline to the
media leads to binding of Tet-VP16 and expression of luciferase. Doxycycline
can be used in a broad range, from 0.01 µg/ml to 10 µg/ml of media without
being toxic for the cells. The doxycycline was titrated to find the optimal con-
centration (Fig.9B). The titration showed a 100-fold induction in the presence of
1µg/ml doxycycline. Higher concentration do not further enhance luciferase ex-
pression. Optimal working conditions were therefore 1µg/ml. Similarly, the stable
cell line was tested for luciferase expression. The doxycycline concentration was
again titrated from 0.1 µg/ml to 10 µg/ml media. Comparable to the transient sit-
uation, 1µg/ml of doxycycline proved to be the optimal working concentrations
and was used for all further experiments (Fig.9A). One difference between the
transient and the stable situation was reduced inducibility in the case of the later.
Indeed, luciferase expression was about 20-fold higher in transiently transfected
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cells compared with the stable system (compare Fig.9A,B).
Figure 9: Inducibility of the 7x tetO Vβ luciferase reporter. A) Luciferase levels
of the episomally stable cell line after 12 hours induction with doxycycline (Dox).
B) In comparison the luciferase levels of the transiently transfected reporter plas-
mid. The Dox concentration were titrated for both situations (0.1, 1 and 10 µg/ml
medium)
MED25 is a critical VP16 interactor in the Mediator complex [Mittler et al., 2003,
Yang et al., 2004]. Notably, the N-terminal domain (NTD) of MED25 exhibits a
strong dominant negative effect on VP16 activation in transient analyses. To test
whether the new system was responsive to the NTD of MED25, the stable re-
porter cell line was transiently transfected with a plasmid expressing NTD, stim-
ulated the cells with 1 µg/ml doxycycline and luciferase activity was monitored.
A strong effect of NTD on luciferase expression would indicate that activation
by VP16 is mainly mediated by Mediator and not by other VP16 interactors. In-
creasing amounts of the NTD expressing plasmids were transfected. The system
proved to be responsive to NTD, in that a 50% drop of luciferase expression was
measured. Indicating that also in the presence of a bona fide chromatin structure
VP16 activation is MED25-dependent (Fig.10). That only a 50% repression of lu-
ciferase expression is measured in this system is probably due to the transfection
efficiency which has been determined to be approximately 50%. In this case (of a
50% transfection efficiency), the maximum expected effect is some two-fold.
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Figure 10: The NTD of MED25 represses VP16 activation. Episomally stable
HeLa cells carrying the 7x tetO Vβ8.1 reporter were transiently transfected with
increasing amounts of NTD (250, 500 and 1000 ng plasmid) Expression of lu-
ciferase was induced with 1 µg/ml doxycycline and measured by a luciferase as-
say.
Luciferase assays used above are relatively slow. The luciferase gene has to be
transcribed and translated before it can be measured. Luciferase levels normally
peak after 12 to 24 hours after induction. A faster readout is provided by the tran-
scribed luciferase mRNA that was measured by real-time RT-PCR. Quantification
of the reverse transcribed DNA was done by real time PCR. The expression of the
luciferase gene was induced with doxycycline for 0, 5, 15, 30, 60 and 120 minutes
and subsequently cells were lysed and total RNA was prepared. For reverse tran-
scription reaction oligo dT primers were used, which leads to transcription of all
polyadenylated mRNA. Subsequently, in the real-time PCR, primers specific for
luciferase and actin were used. The actin levels served as a control to normalize
the PCR reactions. Luciferase transcripts start to be detectable 15 minutes after
doxycycline induction. Full levels of induction were reached after 30 minutes
which then did not change significantly within the next 90 minutes (Fig.11).
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Figure 11: Luciferase transcripts are detectable only 30 minutes after inducing the
Tet-On system by doxycycline. At the indicated time points after induction, RNA
was prepared and analyzed for the amount of luciferase transcripts. The RNA
amount of each time point was corrected to the amount of actin. The mean fold
induction of three independent experiments is shown.
A commonly encountered problem with episomally stable Tet-On systems is that
with time, they loose their inducibility. This loss of inducibility seems to be
related to the packaging of the plasmid with nucleosomes [Pankiewicz, 2004].
Therefore, after some time, the Tet-VP16 can not overcome the inhibition exerted
by the nucleosomes and inducibility is lost. To analyze transcription maintenance,
the stable HeLa cell line harboring the 7x tetO Vβ reporter was cultured for eight
weeks. Luciferase was measured in a weekly manner.
Figure 12: Longterm inducibility of the HeLa Vβ cell line. On the left hand
side, the cells were cultured for eight weeks and the luciferase inducibility was
measured. On the right hand side, the reduction of the inducibility is not due to
lesser amounts of Tet-VP16 in the nucleus (NE: nuclear extract; Cy: cytoplasmic
extract) in older cells as is shown by western blot analysis.
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Newly stable cells showed an approximately 10-fold induction of luciferase. This
induction level could be maintained for up to five weeks. After seven weeks, the
inducibility dropped and remained low at a level of around 2-fold (Fig.12 left
panel). This effect was not due to a loss of Tet-VP16 expression as a western blot
against VP16 showed (Fig.12 right panel), nor to the loss of the reporter plasmid,
since the cells were still grown under selection conditions and the basal luciferase
values remained almost stable. This could be due to the packaging of the plasmid
into chromatin and a relatively weak nucleosome permeability of the Tet-VP16
transactivator. An other reason might be that the episomes get silenced by methy-
lation of histone H3K9, which would result in a heterochromatin like state of the
luciferase gene. This possibility has to be tested in a ChIP experiment. Cells that
lost the inducibility could be monitored for a higher histone H3K9 methylation
status of the episome.
3.1.2 MED25 recruitment is VP16 dependent
MED25 is thought to be the primary target of VP16 in the Mediator complex
[Mittler et al., 2003, Yang et al., 2004]. Evidence for this, stems from biochemi-
cal and functional in vitro data. Even more indicating were reporter assays where
the overexpressed Mediator interaction domain exhibited a strong dominant neg-
ative effect on VP16-driven activation. Nevertheless, this is also a rather artifical
system using highly overexpressed proteins and DNA reporters lacking bona fide
chromatin. To ask the question whether VP16 is able to recruit MED25 to pro-
moters in vivo we performed chromatin immunoprecipitation (ChIP) experiments,
using the previously introduced HeLa 7x tetO Vβ8.1 cell line. Cells were induced
with doxycycline (Dox) for 12 hours. Afterwards, the chromatin was crosslinked
and compared to uninduced cells. The crosslinked chromatin was subjected to
immunoprecipitation using antibodies directed against MED1, MED25 and RNA
polymerase II (Pol II). Pol II serves in this experiment as a marker for transcrip-
tion. In the uninduced situation, the Vβ8.1 promoter is only weakly transcribed
in HeLa cells and only with bound VP16 is it possible to detect transcripts from
this promoter (Fig.11). Consistently, before induction only background levels of
Pol II are detectable on the promoter (Fig.13B). The situation changes after tran-
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Figure 13: VP16-dependent MED25 recruitment to the Vβ8.1 promoter in vivo.
A) ChIP analysis of MED1 and MED25 on the Vβ8.1 promoter. The episomally
stable 7x tetO Vβ8.1 cells were induced for 12 hours with 1µg/ml medium Dox.
The number of PCR cycles were 25, 27 and 29 to ensure analysis in the linear
amplification range. B) ChIP analysis of Pol II from the same experiment served
as a control for transcription induction.
scription is induced where an approximately 20-fold increase of Pol II occupancy
is observed. In the uninduced situation MED25 is not detected at levels above
background (Fig.13A). After addition of doxycycline however, an approximately
18-fold increase of MED25 was seen. This clearly indicates that MED25 can be
recruited to promoters in an activator dependent manner in vivo. Interestingly,
this is not seen for MED1 where levels remained unchanged upon induction, in-
dicating heterogeneity on Mediator complexes or modules of Mediator. The pre-
assembled Mediator complexes present at the promoter may change in subunit
composition, or Mediator complexes lacking the MED1 subunit are recruited by
VP16. For the second situation argues that Mediator complexes have been ob-
served that lack the MED1 subunit [Taatjes and Tjian, 2004, Malik et al., 2005].
A third possibility is that free MED25 is recruited to the promoter. This can not
be ruled out, there is evidence that some 50% of MED25 is not complexed in cell
extracts [Blazek Erik, 2005].
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3.1.3 VP16-dependent Mediator recruitment
Given that MED25 is recruited to the Vβ8.1 promoter in a VP16-dependent man-
ner. It may indicate that the cofactor is incorporated into an already prebound
complex. Alternatively, a MED25 containing but MED1 lacking Mediator is re-
cruited by VP16. Both models would be compatible with the previous result.
Incorporation of MED25 would lead to same MED1 levels but higher MED25
levels. Recruitment of a complex together with MED25 requires the existence
of a MED1 deficient Mediator complex. To investigate this closer by ChIP anal-
ysis, recruitment of other Mediator subunits to the promoter were studied. In
the light of the modular organization of Mediator, the antibodies for this exper-
iment were chosen for their availability at this time. Only a few commercially
available Mediator antibodies were reported to work in ChIP. However, the anti-
bodies could be chosen in a way that every Mediator module (head, middle, tail
and kinase) were targeted at least by one antibody. The antibodies used were
the following: MED13 and Cdk8 are both subunits of the kinase module. The
Cdk8 module is generally considered to have a repressive function within Medi-
ator [Akoulitchev et al., 2000] even though in some reports this does not seem to
be the case [Wang et al., 2005]. It was shown in pull-down assays that Mediator
lacking the Cdk8 module binds to Pol II and that this Mediator complex is the
transcriptionally active fraction in in vitro assays [Naar et al., 2002]. Therefore,
the question arises whether this module would leave the initiation complex upon
transcription induction. MED23 is a subunit restricted to higher eukaryotes that is
located in the tail module where MED23, MED24 and MED16 form a submod-
ule [Ito et al., 2002a, Stevens et al., 2002]. The mouse knock out of MED23 and
MED24, show a greatly reduced activation of transcription by different activa-
tors, even though they are not directly targeted by these activators. Especially the
MED16 subunit is considered to be indicative for Mediator complexes involved
in activated transcription. The location of MED1 was annotated to the middle
module of Mediator. The MED17 located in the head module was shown to bind
directly to VP16 [Ito et al., 1999]. The location of MED25 is not known, although
one can speculate that it is part of the head module, since the EM data show bind-
ing of VP16 in this region [Taatjes et al., 2002]. The antibodies finally used were
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targeted against MED13, Cdk8, MED23, MED1, MED17 and MED25.
Figure 14: VP16-dependent recruitment of Mediator. ChIP analysis of MED25,
MED17, MED23, Cdk8, MED13 and MED1. Tet-On HeLa cells harboring as sta-
ble reporter plasmid either the 7x tetO Vβ8.1 or the 7x tetO CMV promoters were
crosslinked at the indicated timepoints after VP16 activation. Levels of MED25,
MED17 and MED23 increase upon VP16 activation, whereas Cdk8 and MED13
levels decrease, MED1 levels remain invariant on the 7x tetO Vβ8.1 promoter. In-
creased levels of MED25, MED17 and MED23 are observed on the 7x tetO CMV
promoter as well. No accumulation is seen for any of the Mediator subunits in the
control region (oriP).
Tet-On HeLa cells carrying the 7x tetO Vβ8.1 or the 7x tetO CMV reporter plas-
mids (Fig.8) were crosslinked with formaldehyde 0, 5, 30 and 120 minutes after
doxycycline induction. The timecourse was chosen to visualize possible subse-
quent recruitment steps of Mediator subunits. The induction of the system was
monitored by measuring luciferase 12 hours after doxycycline addition. The au-
toradiogram of the ChIP gel shows the rapid recruitment of MED25 already 5
minutes after induction (Fig.14). No additional recruitment of MED25 was ob-
served over the 120 minutes timecourse, arguing for an early steady state scenario.
This result was seen for both promoters, the Vβ8.1 as well as the CMV reporter.
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Following a similar kinetics, the two subunits MED17 and MED23 appeared at
both promoters. Corecruitment of these three subunits argues for combined re-
cruitment of the Mediator head and tail module. MED1 levels already present at
the Vβ8.1 promoter before induction as seen before, remained constant. MED1
levels at the CMV promoter were slightly lower relative to MED25. The pres-
ence of MED1 at the Vβ8.1 promoter before induction seems unlikely to be an
artefact, since the same result was obtained using a different MED1 antibody. Not
only MED1 was found on the Vβ8.1 promoter but MED13 and Cdk8 of the kinase
module as well. None of these two subunits were found at the CMV promoter at
any time. It looks like the middle (assuming MED1 as a marker protein) and the
kinase module (Cdk8, MED13) are present at the Vβ8.1 promoter, only after in-
duction get components of the head (MED17) and of the tail module (MED23)
recruited and the Cdk8 module is lost to form a transcriptionally active complex.
Figure 15: Vβ8.1 promoter sequence. Positions relative to the transcription start
site are indicated by numbers. The consensus sequences are indicated below the
potential binding sites for the different transcription factors.
Additionally it seem possible that a transcriptionally active complex is recruited
that replaces the present complex, as would be seen in the case of the CMV pro-
moter, no Mediator is present before induction and the transcriptionally active
complex gets recruited as one. This might be due to the nature of the different
promoters, the CMV promoter is a minimal viral promoter engineered for low
background activity, whereas the Vβ8.1 promoter is an endogenous promoter in-
cluding different potential activator binding sites [Halle, 1997]. Including sites
for SP1, CRE, AML, ETS and LEF (Fig.15). Especially the binding site for CRE
might account for some basal transcription activity.
It is not possible to decipher whether a complete transcriptionally active Mediator
complex is recruited by VP16 or if a prebound transcriptionally inactive “core”
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Figure 16: VP16-dependent recruitment of Mediator. Short term ChIP analysis
of the Tet-On HeLa cells carrying the 7x tetO Vβ8.1 reporter plasmid. MED25,
MED17 and MED23 are recruited within the first 3 minutes after VP16 activa-
tion. The Cdk8 subunit is lost at the same time, whereas MED1 levels remain
unchanged.
Mediator gets “loaded” with head and tail module and thus activated by VP16.
The presence of three Mediator subunits (MED1, Cdk8 and MED13) on the Vβ8.1
promoter before induction of transcription argues for the model that a core com-
plex is prebound on the promoter. To shed more light into this aspect, a short term
kinetic was applied. HeLa cells carrying the 7x tetO Vβ8.1 reporter plasmids
were crosslinked with formaldehyde 0, 1, 3 and 5 minutes after induction. The
ChIP analysis showed that MED17, MED23 and MED25 are perfectly corecruited
in time, showing up approximately after 3 minutes of induction (Fig.16). Cdk8
leaves the promoter as the other three subunits appear and MED1 levels remain
unchanged. A Pol II antibody was included into this experiment,demonstrating
that Pol II is not prebound together with the “core” Mediator but is recruited after
3 minutes. Again, this perfectly correlates to the loss of the Cdk8 module, indicat-
ing that occupancy of the Cdk8 module and Pol II mutually exclusive. Consistent
with an elongating Pol II, not Mediator but Pol II is found in the coding region.
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In conclusion, the data showed that Mediator is recruited to promoters by VP16
in vivo. Moreover, the kinase module of Mediator is lost during transcription acti-
vation. Additionally, Pol II and active Mediator lacking Cdk8 enter the promoter
with similar kinetics. There might be a possibility of dynamic changes in the
subunit composition of Mediator upon transcription activation.
3.1.4 VP16-dependent chromatin modification
Histones can be modified by transcription cofactors. These histone modifications
are a hallmark of transcribed genes. HAT activity leads to the decompaction of
the chromatin whereas HDAC has a reverse effect. Histone acetylation as well as
certain histone methylation may correlate to transcribed genes and are thought to
form a code that leads to binding of transcription cofactors. For example, acety-
lated histone H4 and acetylated H3K9 as well as trimethylated histone H3K4
and dimethylated H3K79 are frequently found on actively transcribed regions
[Jenuwein and Allis, 2001, Zhang and Reinberg, 2001, Kouzarides, 2002]. VP16
is known to interact with at least two different histone acetyltransferases, these are
the CBP/p300 [Kraus et al., 1999, Ikeda et al., 2002] and the yeast SAGA com-
plex [Utley et al., 1998]. The established inducible VP16 cell system provides
a tool that allows to monitor the modification state of histones upon VP16 ac-
tivation. Additionally the presence of the two HAT activities of CBP/p300 and
hGCN5 on the promoter can be examined.
Tet-On HeLa cells carrying the 7x tetO Vβ8.1 or the 7x tetO CMV reporter plas-
mids were crosslinked with formaldehyde 0 and 30 minutes after doxycycline
induction. The autoradiogram of the ChIP shows a VP16-dependent recruitment
of both CBP/p300 and the hGCN5 histone acetyltransferases to the promoters
(Fig.17A). Accumulation of both HATs is approximately equally strong on both,
the Vβ8.1 and the CMV promoters despite the more distal position of the TRE
on the Vβ8.1 promoter. The accumulation is restricted to the promoter region,
no increased levels of CBP/p300 nor hGCN5 was visible in the coding or the
control region. To monitor the histone modification state of the two promoters,
antibodies directed against acetylated histone H4 and H3K9 as well as antibodies
directed against trimethylated histone H3K4 and dimethlyated H3K79 were used
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Figure 17: VP16-dependent histone modifications and recruitment of HAT activ-
ities. A) ChIP analysis, Tet-On HeLa cells carrying either the 7x tetO Vβ8.1 or
the 7x tetO CMV reporter plasmids were crosslinked 0 or 30 minutes after VP16
activation. An increase of CBP/p300 and GCN5 but no change in the levels of
histone modifications is seen. B) ChIP analysis, Tet-On HeLa cells carrying the
7x tetO Vβ8.1 reporter plasmid were crosslinked at the indicated time points after
VP16 activation. A dramatic increase of dimethylated histone H3K79 is observed.
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(Fig.17). Despite recruitment of CBP/p300 and hGCN5, no increase of acety-
lated histones were observed in the ChIP experiment. Histone H4 and the more
specific H3K9 get only moderately acteylated upon VP16 activation at the pro-
moter or the coding region (Fig.17A). This may be a consequence of the already
high histone modification levels at the episomal reporter before VP16 activation.
Additionally only a minor change of trimethlyated histone H3K4 was observed,
which may be for the same reason. In contrast, a strong increase of dimethylated
histone H3K79 of about 20-fold was seen on the promoter and the luciferase gene
(Fig.17B). 5 minutes after induction, enhanced levels of K79 dimethylation were
observed, which further increased 30 minutes after induction. In the coding re-
gion the observed accumulation of dimethylated K79 was delayed and was not
yet visible 5 minutes after induction. The only known methyltransferase that is
responsible for this modification is hDot1L.Interstingly, histone modifications are
lower in the oriP control region. This finding is in accordance with reports from
the Lieberman laboratory where they show that histone modifications spread over
a large distance on the EBV episome [Chau CM. and Lieberman PM., 2004] and
that the histones adjacent to the oriP region are the most heavily modified but not
the oriP region itself [Zhou J., 2005].
In conclusion, a recruitment of the two HAT activities CBP/p300 and hGCN5 by
VP16 in vivo occurs. Yet the system failed to detect increasing levels of acetylated
histones H4 and H3K9. This could be due to increased HDAC levels as were
seen in some preliminary experiments. However, increased levels of dimethylated
histone H3K79 could be shown, a modification specific for actively transcribed
genes.
3.1.5 VP16-dependent recruitment of GTFs and RNA processing factors
The first step in transcription is the formation of the preinitiation complex. It starts
with the binding of TBP to the TATA box and ends with the recruitment of TFIIH
that phosphorylates the CTD of Pol II leading to promoter clearance of RNA poly-
merase II. To monitor PIC formation, antibodies directed against TFIIB and TFIIH
were used. TFIIB acts in an early step of PIC assembly, whereas TFIIH marks the
endpoint of PIC formation. PIC formation in activated transcription is not only
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supported by Mediator but also by other positive cofactors like PC4. PC4 was first
characterized as a component of the USA fraction were it positively influences ac-
tivated transcription [Ge and Roeder, 1994, Kretzschmar et al., 1994a]. PC4 is a
direct interactor of VP16, it is involved in PIC assembly and was shown to bind
to DNA, hence PC4 was chosen for this experiment.
Transcription stops at the termination signal and the nascent mRNA is cleaved
and polyadenylated at the polyA signal (AAUAAA). The factors involved in this
process are the cleavage and polyadenylation factor (CPSF) that acts together with
the cleavage stimulatory factor (CstF) and the cleavage factors I and II (CF I, CF
II). The inducible VP16 cell system gave us the possibility to take a closer look
not only into PIC formation but also into the connection of transcription initiation
and transcription termination. The Pol II and MED25 antibody were included to
monitor Pol II and Mediator recruitment and act as a positive control.
Tet-On HeLa cells carrying the 7x tetO Vβ8.1 or the 7x tetO CMV reporter plas-
mids were crosslinked with formaldehyde 0 and 30 minutes after doxycycline
addition. Mediator, TFIIB, TFIIH and Pol II are corecruited to the promoters and
form a complete PIC as would be expected (Fig.18A). Whereas Mediator, TFIIB
and TFIIH were seen at promoters but not in the coding and the control region,
Pol II was also observed on the luciferase gene, which is indicative for ongoing
transcription. PC4 and CPSF are also recruited by VP16 to the promoter, estab-
lishing a connection between transcription initiation and mRNA polyadenylation.
Notably, PC4, CPSF and CstF64 were corecruited at a later timepoint than Medi-
ator and Pol II (Fig.18B). Whereas Mediator and Pol II appeared within minutes
(Fig.14), PC4, CPSF and CstF64 appeared between 5 and 30 minutes after induc-
tion at the promoter.
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Figure 18: VP16-dependent recruitment of general transcription factors and
polyadenylation factors. A) ChIP analysis, Tet-On HeLa cells carrying either the
7x tetO Vβ8.1 or the 7x tetO CMV reporter plasmid were crosslinked 0 or 30
minutes after VP16 activation. Of all the factors is only Pol II found in the cod-
ing region, the other factors are exclusively recruited to the promoter. B) Time-
course ChIP analysis, Tet-On HeLa cells carrying the 7x tetO Vβ8.1 reporter were
crosslinked at the indicated timepionts after VP16 activation. PC4 together with
the polyadenylation factors CPSF and CstF64 were recruited at a later stage dur-
ing transcription initiation than the other transcription factors (Fig.14 and Fig.17).
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There are reports that show an interaction between PC4 and CstF64 [Calvo O., 2001,
Calvo O., 2005], therefore a concerted action of at least PC4 and CstF64 seems
possible. By the dual role of PC4 to facilitate PIC formation and in binding to the
polyadenylation machinery, it might contribute to the link between transcription
initiation and transcription termination.
The data show the in vivo recruitment of components of the preinitiation complex
as well as of the polyadenylation machinery. Recruitment of GTF’s and Medi-
ator is restricted to the promoter regions. The corecruitment of PC4, CPSF and
CstF64 might point towards a bridging function of PC4 between the initiation
complex and the polyadenylation machinery. However, these data alone can not
prove this possibility directly. Instead, they could also be consistent with a role
of CPSF/CstF in a later phase of transcription. In addition, the late recruitment of
PC4 might also indicate a function involved in late transcription initiation or even
elongation. Notably, luciferase mRNA was only detected some 15 minutes after
VP16 activation (Fig.11). This might reflect a delay in formation of full length
transcripts but could also reflect the time request for splicing and RNA export.
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3.2 In vitro PIC assembly
The ChIP technology is a valuable tool to study chromatin related molecular pro-
cesses in vivo. However, it is inefficient to decipher molecular processes on genes.
For this, in vitro systems are expected to be more efficient. For example tran-
scription initiation complexes may be selectively formed and analyzed in vitro
which then become converted into elongating complexes only upon addition of
nucleotides.
Figure 19: A MED25 containing Mediator complex (A-Med) is necessary for
VP16-dependent recruitment of Mediator. Left panel, in a solid phase assay, bi-
otinylated promoter DNA was immobilized on streptavidin coated beads. In the
presence of VP16 Mediator was recruited from nuclear extracts (NE) but not from
MED25-depleted nuclear extracts (∆MED25). Right panel shows a control for
the MED25 depletion.
Towards a solid phase assay, biotinylated DNA fragments were immobilized on
streptavidin coated paramagnetic particles to assemble a preinitiation complex
(PIC). The DNA fragment used contained the promoter fragment MRG5
[Meisterernst et al., 1991], that consists of the HIV core-promoter sequence and
the adenovirus major late (ML) initiator under the regulation of 5 Gal4-binding
sites. It has previously been shown that cell extracts contain both MED25-Mediator
(A-Med) and other Mediator complexes lacking this specific subunit [Mittler et al.,
2003]. It was first analyzed whether Gal-VP16 dependent recruitment of Medi-
ator is observed in a MED25-depleted nuclear extract (∆MED25). Recruitment
of Mediator was monitored by a MED7 antibody. TBP was used as a control be-
cause this factor does not bind efficiently to Mediator [Mittler et al., 2003]. In
a normal nuclear extract (NE), a Gal-VP16 dependent recruitment of MED7 is
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indeed seen (Fig.19) whereas in a MED25-depleted nuclear extract no Gal-VP16
dependent Mediator recruitment could be observed. Highlighting again that a
MED25-containing Mediator complex (A-Med) is indeed crucial for Gal-VP16
dependent recruitment. In both nuclear extracts, TBP binds to the DNA regard-
less of the presence of Gal-VP16 (Fig.19).
Figure 20: Addition of nucleotides (NTP) releases the kinase module as well as the
MED1 subunit form the Mediator complex. In a solid phase assay, biotinylated
promoter DNA was immobilized on streptavidin coated beads. In the presence
(+) VP16, Mediator, together with Pol II and TFIIH are recruited to the Promoter.
Addition of 0.5 mM of nucleotides releases Cdk8 and MED1 from the bound
Mediator complex.
From the ChIP analysis it was predicted that the kinase module of the Media-
tor is not recruited by Tet-VP16. Additionally, MED1 should not be enriched,
whereas other Mediator subunits should. To examine this, proteins retained by the
immobilized template after addition of Gal-VP16 were analyzed by SDS-PAGE
and subsequent immunoblotting. In the absence of the activator, moderate levels
of Pol II and of the general transcription factor TFIIH, but not of Mediator could
be detected (Fig.20). Addition of Gal-VP16 to the immobilized template signif-
icantly enhances Pol II and TFIIH levels. Under these conditions the Mediator
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subunits MED1, MED7, MED25 and Cdk8 accumulate at the promoter. This un-
derlines the need of an activator for Mediator binding, but raised questions about
Cdk8. After addition of nucleotides (NTP), MED7 and MED25 are retained at the
template. The other two Mediator subunits MED1 and Cdk8 are lost from the ini-
tiation complex. Pol II and TFIIH levels are reduced to the same level before ad-
dition of the activator. The loss of Pol II after addition of nucleotides is expected,
since under these conditions the CTD of Pol II becomes phosphorylated and Pol II
clears the promoter. Retention of TFIIH and Mediator at the promoter is observed
and resembles most likely a scaffold complex as was discussed in yeast. The
scaffold complex is thought to facilitate transcription reinitiation. The Mediator
complex that is retained at the promoter lacks the kinase module that is a hallmark
of the small, transcriptionally active Mediator complexes (PC2, CRSP, B-Med).
Additionally, it lacks the MED1 subunit as well. Recently, Mediator complexes
lacking MED1 have been described as PC2-like complex by the Roeder labora-
tory and the CRSP-2 complex by the Tjian laboratory. The VP16 specific Medi-
ator (A-Med) is similar to these two complexes, it remains to be shown whether
the MED25 subunit is specific for VP16 targeted Mediator complexes only. An
interesting point however is that a complete TRAP-like Mediator complex is re-
cruited by VP16 and that the transition into the specific A-Med complex is NTP
dependent.
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Figure 21: Phosphorylation-dependent remodeling of the Mediator complex
within the preinitiation complex. A) Addition of ATP releases Pol II and MED1
from the PIC. However, phosphorylation alone still retains Cdk8 on the template.
Phosphorylation in combination with ongoing elongation (+ AUC) releases Cdk8
from the PIC. B) Autoradiogram of proteins retained at the promoter in the situa-
tion were a complete NTP mix together with 32P γATP was added to the reaction.
Addition of H8 prevents phosphorylation of most proteins with the exception of a
band of around 100 kDa. C) Autoradiogram of proteins lost from the PIC. After
PIC formation, the complexes were washed and NTP, ATP and H8 together with
32P γATP was added to the reaction. Released proteins from the PIC were sub-
jected to TCA precipitation and phosphorylated proteins were visualized. Bands
sensitive to H8 are marked by asterisks. D) Schematic overview of the experiment.
Addition of a complete nucleotide mix leads to elongation and run-off of Pol II.
To address the question whether phosphorylation plays a role, ATP and the kinase
inhibitor H8 were used. Again, addition of 0.5 mM NTPs to the reaction led to the
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loss of the MED1 and Cdk8 subunit of Mediator. Treatment of the nuclear extract
with the kinase inhibitor H8 for 50 minutes before addition of the NTPs, blocked
the loss of Cdk8 and of Pol II (Fig.21C). This may indicate a role of phosphoryla-
tion in dissociation of Cdk8. Phosphorylation lead to a loss of MED1, but not the
Cdk8 subunit, indicating that the loss of Mediator-Pol II interaction is not suffi-
cient for the loss of the kinase module. It is unclear whether Mediator complexes
of modules of it fall off the template alone or in combination with Pol II. Only
after addition of ATP, UTP and CTP (AUC), a loss of Cdk8 could be observed.
Indicating that in addition to phosphorylation, elongation seems to be necessary
to remove the kinase module of the Mediator complex (Fig.21A). However there
were exceptions when reduced levels of Cdk8 were already observed with ATP
alone. This raises the question about which proteins become phosphorylated and
whether they remain at the promoter or if they are lost during transcription acti-
vation (Fig.21B and C). To start answering this question, preliminary experiments
were carried out. Together with ATP or a complete NTP mix, radioactive 32P-
γATP was added to the reaction to label phosphorylated proteins. Labeled pro-
teins retained at the promoter were analyzed by SDS-PAGE and subsequent au-
toradiography (Fig.21B). There are several proteins that become phosphorylated.
Most of this phosphorylation could be blocked by addition of H8, indicating their
relevance in transcription activation as was shown before (Fig.21A). The phos-
phorylation of four proteins (marked with an asterisk) were sensitive to H8 and
therefore the most likely candidates for being responsible in regulating open com-
plex formation and remodeling of the Mediator complex. The identity of these
proteins remains to be determined by other means, like masspectrometry. La-
beled proteins released from the PIC were concentrated from the supernatant by
TCA precipitation, separated on an SDS-PAGE and visualized by autoradiogra-
phy (Fig.21C). Indeed, one double band at around 50 to 60 kDa shows up when
either ATP or an NTP mix was added to the reaction. This double band is lost
when the PIC was pretreated with the kinase inhibitor H8. About the identity of
the protein can only be speculated, however the size is close to Cdk8 which often
migrates as a double band according to Western blot analysis. Unfortunately, the
recovered protein from the supernatant proved to be too little to be analyzed by
Western blot.
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3.3 MED25, a novel Mediator subunit
3.3.1 Cellular distribution of MED25
Scanning the MED25 sequence for targeting signals, using programs predicting
the cellular localization, none of them could find a nuclear localization signal
(NLS). To investigate this aspect, indirect immunofluorescence (IF) experiments
were performed in adherent HeLa cells.
Exponentially growing cells were fixed and incubated with the MED25 mono-
clonal antibody to visualize the protein by confocal microscopy. Immunofluo-
rescence of endogenous MED25 shows a predominantly nuclear but weak and
diffuse staining. However the signal is only slightly stronger than the negative
control (HA antibody) which renders the analysis somewhat ambiguous. As an
Figure 22: Endogenous MED25 is visualized by a monoclonal antibody (VC1
9C2) and a secondary anti-rat antibody conjugated to FITC (green). The MED25
signal is only slightly above the background signal of the HA antibody (negative
control). In contrast to the NC2α signal as a positive control, that shows a strong
nuclear staining.
example for a clear nuclear staining, the positive control (NC2) shows a strong
nuclear signal (Fig.22). To further substantiate MED25 localization, HeLa cells
were transfected with a Flag-MED25 expression vectors. The tagged protein can
be detected by two different antibodies either directed against MED25 or against
the Flag-tag. The overexpressed protein clearly localizes to the nucleus, only
the nucleoli are excluded from the staining (Fig.23). The protein is evenly dis-
tributed and no preferential localization is evident (e.g. speckles). As expected, if
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Figure 23: MED25 localizes to the nucleus. HeLa cells were transfected with
Flag-MED25 and stained with antibodies against Flag (M2; red) and MED25
(VC1 9C2; green). The overlay shows a nice colocalization of the two indepen-
dent antibodies.
the MED25 monoclonal antibody and the Flag specific antibody (M2) recognize
solely the target protein, the signals colocalize perfectly.
3.3.2 PTOV1 shares some homologies with MED25
MED25 is not the only protein that carries an ACID domain. A second protein,
termed prostate tumor overexpressed protein (PTOV1) carries two ACID domains
and lies next to MED25 on chromosome 19q13.33. The 415 amino acid long
PTOV1 protein consists virtually of the fusion of two ACID domains (Fig.24A).
PTOV1 is overexpressed in prostate tumor cells. It was shown that it is a mito-
genic protein that shuttles between the cytoplasm and the nucleus in a cell cy-
cle dependent manner and promotes entry into the S phase [Santamaria A., 2003,
Santamaria A., 2005]. Overexpression of PTOV1 strongly induces cell prolifera-
tion whereas depletion represses proliferation. To investigate the possibility that
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MED25 is also shuttling between the cell compartments, nuclear extracts derived
from synchronized Raji cells were monitored in Western blot analysis.
Figure 24: A) Cartoon of MED25 and POTV1 indicating the shared ACID do-
mains in light grey. B) Westernblot analysis of MED25 expression during the cell
cycle. Nuclear extracts from synchronized Raji cells were separated on a 12%
SDS-PAGE gel. The MED7 subunit is used as a marker for Mediator. (MED7
3E12 rat monoclonal, 1:20 dilution in TBS-T 1% milkpowder; MED25 9C2 rat
monoclonal, 1:20 dilution in TBS-T 1% milkpowder).
Exponentially growing Raji cells were harvested in an Elutriator. Cells in different
phases of the cell cycle could be obtained, namely from the phases G1, G1/S, S,
S/G2 and G2. Nuclear extracts were produced from each cell fraction (kindly pro-
vided by A. Schepers). Equal amounts of proteins were subjected to SDS-PAGE,
blotted and probed with MED7 and MED25 antibodies. MED25 was found in all
cell fractions and neither increased nor decreased in any of the fractions assayed
(Fig.24B). MED7 serving as a control for the presence of Mediator in the extracts
behaved in the same way.
In conclusion, the immunofluorescence of overexpressed MED25 showed a nu-
clear localization, indicating an efficient transport into the nucleus. Furthermore,
localization of endogenous MED25 into the nucleus is independent of the phase
of the cell cycle.
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3.3.3 MED25 binds CBP in vitro
Immunoprecipitation of Mediator also precipitates CBP/p300 as was shown by
Westernblot and masspectrometry [Stuehler Thomas, 2005]. It was shown that
VP16 binds directly to CBP/p300 [Kraus et al., 1999, Ikeda et al., 2002] as it does
to MED25 [Mittler et al., 2003, Yang et al., 2004]. To ask whether MED25 and
CBP interact directly and to map the interaction surface within the proteins, a GST
pull down assay was employed. CBP can be roughly divided into three regions.
Figure 25: MED25 binds CBP in vitro. A) Structure of CBP and the used GST-
derivatives are indicated as well as the MED25 constructs used in this assay. B)
GST-pull down of 35S-labeled MED25 proteins on a GST-CBP matrix. 20 µg of
GST-fusion proteins were blocked with 60 µg of BSA and incubated with 5 µl of
radioactive labeled MED25 proteins in BC150 buffer. Shown is the autoradiogram
after separation of the proteins on an SDS-PAGE.
The N- and the C-terminal regions are known to bind to a myriad of transcription
factors. The central region harbors the Bromo and the HAT domain (Fig.25A).
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GST, GST-CBP1-1098 , GST-CBP1098-1710 and GST-CBP1678-2441 deletion
constructs were purified and immobilized on a GST columns. MED25 full length
and MED25∆ACID proteins were translated in vitro in a coupled transcription
and translation reaction that allowed labeling with 35S-Methionine (Fig.25A).
The radioactive labeled MED25 proteins were incubated together with the GST-
CBP deletion constructs or GST alone. The N-terminal region of CBP, GST-
CBP1-1098 and the C-terminal GST-CBP1678-2441 bind the MED25 full length
protein slightly stronger than the central region of CBP (Fig.25B).
The MED25∆ACID construct is not bound by any of the CBP deletion proteins,
indicating an essential role of the ACID domain in binding CBP. Although, the
question whether the ACID domain alone is sufficient for interaction with CBP
remains open, the result would imply a simultaneous binding of VP16 to MED25
and CBP. VP16 binds to CBP via its H2 domain, which leaves the H1 domain
free for Mediator interaction. For the future it would be interesting to see whether
VP16-H1 coprecipitates CBP with MED25 at low stringency.
3.3.4 Differential urea dissociation of Mediator subunits
Using differential dissociation by urea, the Kim laboratory could demonstrate
that yeast Mediator can be dissociated into subcomplexes [Sang Jun Han, 2001]
[Jong Seok Kang, 2001], namely the Mediator tail/middle subcomplex and the
head subcomplex. The association of the newly identified Mediator subunit MED25
to one of the subcomplexes is unknown. To address this issue, human Mediator
from HeLa nuclear extracts was immobilized on anti-MED15 antibody agarose
beads. The retained proteins were examined by Western blot analysis after exten-
sive washing with urea-containing buffer. MED15 is the mammalian homologue
of the yeast Gal11 subunit that localizes to the tail subcomplex of Mediator. The
tail and middle subcomplex were shown to be the most resistant ones to treatment
with urea [Han et al., 2001].
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Figure 26: Differential dissociation of Mediator components by urea. Mediator
was immobilized by MED15 antibody beads and washed with buffer containing
0M (IP) to 3M urea (urea). The remaining Mediator subunits on the antibody
beads were subjected to SDS-PAGE followed by western blot analysis.
Mediator was immunoprecipitated using MED15 antibody columns. The im-
munoprecipitation was done under standard conditions using 150 mM KCl for
precipitation and in the BC150 wash buffer (for detail see Materials and Methods
2.9.3). 2M urea washes removed most of MED25 from the MED15 immobilized
beads. MED17, a subunit of the head subcomplex, was only removed after 3M
urea washes (Fig.26). On the other hand, MED1 and MED7 were retained on the
antibody beads even after 3M urea treatment. MED1 and MED7 are both subunits
of the middle subcomplex. MED25 is among the first proteins that are lost from
the complex, in accordance to the data from Kim and colleagues [Han et al., 2001]
this would point towards a localization of MED25 within the head subcomplex of
Mediator. However, the MED25-Mediator interaction might be weak and and only
transient as was suggested from the Conaway laboratory [Sato et al., 2004]. If this
is the case, MED25 could be washed away by urea independent of its respective
subcomplex. However the finding that MED25 does not associate with the tail nor
with the middle, but rather with the head subcomplex of Mediator would be in line
with previous reports that VP16 crosslinkes to MED17 [Ito et al., 1999] and with
electron microscopy data that locates Mediator bound VP16 to the head domain
[Taatjes et al., 2002].
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3.3.5 Towards the structure of the ACID domain
The activator interaction domain (ACID) of MED25 is a novel protein interaction
domain. The human ACID domain binds strongly to the activation domain of the
Herpes simplex virion protein 16 (VP16) [Mittler et al., 2003, Yang et al., 2004],
and LANA-1 [Roupelieva, 2005]. The drosophila ACID domain binds to differen-
tiation inducing factor (DIF) and to heat-shock factor (HSF) [Kim TW, 2004]. All
of these activators are viral proteins. A cocrystal structure with VP16 at atomic
resolution would allow us to study the interaction surface of the two proteins and
the many existing mutations within the VP16 activation domain could be better
explained. Additionally, from a pharmaceutical point of view this domain might
act as a potent Herpes virus inhibitor. To learn more about the ACID domain we
decided to determine the crystalstructure in collaboration with P. Cramer.
To determine the exact localization of the domain borders, several N- and C-
terminal deletion constructs were generated. Six different constructs, spanning
amino acids 345-560, 345-548, 393-560, 393-548, 426-560 and 426-548 were
generated (Fig.27A). The N-terminal deletions were chosen to delete poorly pre-
dicted secondary structures and the C-terminal deletions to remove part of a poly-
proline stretch. First, all this constructs were expressed in E.coli and tested for
solubility. The soluble fractions and the insoluble pellets were compared on an
Coomassie stained SDS-PAGE gel in parallel with an uninduced cell aliquot. All
proteins with the exception 426-560 and 426-548 of were expressed at high levels
and were present in the soluble fraction.
Specific binding of the truncated domains to VP16 was investigated. Immobi-
lized GST-VP16 H1 and H1mt were incubated with E.coli lysate containing the
different ACID domains (amino acids 345-560, 345-548, 393-560 and 393-548).
Binding to VP16 H1 was visualized on a Coomassie stained SDS-PAGE. As ex-
pected all proteins bound to H1 but not to H1mt (Fig.27B), and were therefore
specific.
83
3.3 MED25, a novel Mediator subunit 3 RESULTS
Figure 27: Primary sequence of ACID and specific binding of the ACID deletion
proteins to VP16. A) Sequence of the human ACID domain. Depicted are the sec-
ondary structure prediction as well as the start and end points of the used deletion
constructs. B) All of the deletion proteins bind to the full length VP16 activa-
tion domain (VP16), and the H1 activation domain (H1), but not to the mutated
H1 activation domain (H1mt), indicating specific binding. Shown is a Coomassie
stained 15% SDS-PAGE of eluted proteins.
Binding to GST-VP16 could also be seen when GST-VP16 was coexpressed to-
gether with the ACID constructs. E.coli were transformed with two different plas-
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mids, one plasmid encoding for GST-VP16 and the second plasmid for a 6xHis-
tagged ACID domain. The cells were lysed and the cleared lysate was subjected to
either a Ni-column or a GST-column (for details see Materials and Methods 2.9.2;
2.9.5 and 2.9.6). When using a Ni-column to purify the ACID domain, GST-VP16
always copurified (Fig.28) and vice versa.
Figure 28: 6xHis-MED25 can be copurified with GST-VP16. E.coli expressing
both 6xHis-MED25 and GST-VP16 were lysed and the proteins were purified
either over a GST-column or a Ni-column, respectively. Using the Ni-column,
GST-VP16 is copurified together with 6xHis-MED25. Shown is a Coomassie
stained 12% SDS-PAGE.
To determine the exact domain borders of the ACID domain, purified proteins
were incubated at 37◦C together with Trypsin and subjected to limited protease
digestion. Correctly folded domains show a higher resistance towards proteolysis
than unfolded regions, thus trimming the domain to its minimal form. For trypsin
treatment, 1µg of the protease was added to 20 µg of purified protein. Digests
were done in BC150 buffer supplemented with CaCl2to a final concentration of
4 µM. The mixture was incubated at 37◦C for 1 min, 3 min, 10 min and 30 min.
The reactions were stopped by addition fo SDS sample buffer and were heated
immediately to 95◦C for 5 min. For proteinase K treatment, 1 µl od dilutions of the
proteinase (3 µg/µl, 0,3 µg/µl, 0,03 µg/µl, 0,003 µg/µl) were added to the protein
samples. The mixtures were incubated on ice for 1 hour. All of the four deletion
proteins tested proved to be stable during the limited proteolysis experiments. One
exception was the protein spanning amino acid 345 to 560 which was degraded
to some extent. (Fig.29). The experiment was repeated with proteinase K instead
of Trypsin. Proteinase K has a broad specificity and cuts proteins randomly. The
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outcome of this experiment was similar to the one with Trypsin. Again the protein
spanning the region from amino acid 393 to 548 was the smallest stable fragment.
For crystallization trials, this construct was used.
Figure 29: Protease protection assay to determine and verify the ACID domain
borders. Purified deletion proteins were incubated with Trypsin for the indicated
periods of time. The proteins were separated on a SDS-PAGE and stained with
Coomassie for analysis. All the proteins are extremely resistant towards the pro-
tease, indicating a stabile folded protein domain. Degradation product is indicated
by an asterisk.
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4 Discussion
4.1 Establishment of an inducible VP16 model system
To study transcription initiation in vivo one is in need of a system that allows to
turn on transcription of a specific gene of interest. In reporter assays, the effect
of a protein on transcription is measured by the expression of the exogenous lu-
ciferase gene. The reporter plasmid (e.g. pGL2-MRG5) used in such an assay
consists of a model promoter (e.g. HIV) that is under the control of exogenous
activator binding sites (5x Gal). These reporter plasmids are transiently cotrans-
fected together with a plasmid coding for the transactivator (e.g. Gal-VP16). The
advantage of such a system is clearly that the effects of cofactors on transcription
can be studied in vivo. However, to visualize transcription cofactors by ChIP anal-
ysis these transient systems are of no use. In most reports to date, transcription is
studied on endogenous gene promoters by ChIP analysis. The signals to turn tran-
scription on in these mammalian systems are based on hormones like estrogen
[Metivier R., 2003], serum induction [Wang et al., 2005] and cell differentiation
[Soutoglou and Talianidis, 2002] or galactose induction in yeast [Bryant, 2003].
Even if the gene promoter under investigation is the major target of these signals,
secondary effects can not be excluded. In the system using serum induction for
example, the Egr1 and Egr2 genes are not the only genes affected by the signal
but over 20 other genes as well [Wang et al., 2005]. Therefore the use of an ex-
ogenous transactivator and signal to induce transcription of a model gene would
be a nice system to study transcription initiation timely resolved in ChIP assays.
Conventional stable cell lines with integrated reporter genes into their genomes
can produce positioning effects dependent on the locus of the integration. To cir-
cumvent this complication, EBV (Epstein-Barr Virus) based vectors that replicate
episomally carrying a suitable promoter and a Tet-VP16 expression cassette al-
low induction of VP16-dependent transcription of the luciferase gene. This vector
system has several advantages: (i) it was shown for these mini-episomes to be
packed into chromatin [Chau CM. and Lieberman PM., 2004, Zhou J., 2005], (ii)
the transactivator is unique and targets only one specific promoter (iii) the transac-
tivator as well as the promoter are interchangeable with other activation domains
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or promoter sequences.
The transactivator Tet-VP16 is a fusion protein of the DNA binding domain of the
tetracycline repressor and the activation domain of VP16. The VP16 protein is
a potent activator that controls the transcription of immediate early genes of the
herpes simplex virus through interaction with host cell factors. The mechanism
of transcription stimulation by VP16 has been studied extensively. VP16 pro-
motes the enhancement of transcription rates and increase in the number of func-
tional active promoters [Ranish et al., 1999]. It facilitates open complex formation
[Jiang et al., 1994] and increases the processivity of Pol II [Yankulov, 1994]. The
expression cassette for the luciferase gene, consists of a model promoter under
the regulation of the tetracycline-response element (TRE) and the SV40 poly(A)
signal. The TRE contains seven direct repeats of a 42-bp sequence (7x tetO) rec-
ognized by the DNA binding domain of the tetracycline repressor. Addition of
doxycycline allows Tet-VP16 to bind specifically to the TRE and leads to the ex-
pression of luciferase. The model promoters used in this study were the T-cell
specific promoter of the TCRβ locus, the Vβ8.1 and the minimal core of the
CMV promoter (Fig.8). The functionality of the system was tested by monitor-
ing luciferase expression (Fig.9 and 10 and by detection of luciferase mRNA by
RT-PCR (Fig.11). The system is fast responding to doxycycline stimulation and
luciferase mRNA could be measured 15 minutes after induction. Binding of Tet-
VP16 is even faster as could be shown by D.L. Spector and colleges by real-time
fluorescent microscopy [Janicki et al., 2004].
The inducibility of the Vβ8.1 cell line was monitored over the course of eight
weeks (Fig.12). Over time, the cells lost their inducibility and after six weeks,
hardly any luciferase could be measured anymore. This loss of inducibility is not
due to the loss of Tet-VP16 as could be shown by a western blot against VP16.
The levels of expressed VP16 is the same regardless of the inducibility of the
cells. A loss of the reporter plasmid can also be ruled out, since the cells were kept
constantly under selection pressure. The explanation might lie in the positioning
of the nucleosomes together with the lesser nucleosome penetration potential of
the Tet-repressor compared to the Gal-DNA binding domain [Pankiewicz, 2004]
and the relatively weak transcription potential of the Vβ8.1 promoter.
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Taken together, this newly established episomally stable vector system allows
rapid activation of specific model promoters in vivo, and allows to study tran-
scription in the context of chromatin.
4.2 Formation of the transcription complex in vivo
Induction of transcription requires the formation of the preinitiation complex (PIC)
on the promoter, comprising the six general transcription factors TFIIA to F and
Pol II [Berk, 1999]. This assembly process normally takes place at the core pro-
moter, which includes defined sequence elements within the 35 bp upstream and
downstream of the transcription start site in human and drosophila. These el-
ements include the TATA element (TBP binding), TFIIB recognition element
(BRE), Initiator element (INR) and Downstream promoter element (DPE)[Smale
and Kadonaga, 2003]. The most prominent core promoter sequence is the TATA
element which is bound by TBP that belongs to the 15 subunit TFIID complex.
TBP binding promotes DNA bending and is the first step in transcription machin-
ery assembly [Kim et al., 1993b]. Next, TFIIA binds and stabilizes the TBP/DNA
complex [Geiger et al., 1996, Tan et al., 1996]. TFIIB directly contacts TBP and
DNA [Nikolov D. and S., 1995]. Together they form the platform on which Pol II
and TFIIF can assemble. After the recruitment of TFIIE and TFIIH, ATP depen-
dent promoter opening can occur ([Hahn, 2004]). These basic mechanisms have
been elucidated in various in vitro systems in the past [Orphanides, 1996]. Only
in recent years it became possible by ChIP technology to investigate transcription
machinery assembly in vivo. In an estrogen inducible in vivo system preinitiation
complex formation was studied on the example of the estrogen receptor-αtarget
pS2 gene promoter [Metivier R., 2003]. An ordered and interestingly, cyclical
recruitment of cofactors could be observed.
In this thesis PIC formation was monitored in vivo by ChIP analysis of TFIIB,
TFIIH, PC4, Mediator and Pol II (Fig.18). Not so much the formation of the
PIC was in the main focus but the interaction and possibly crosstalk between the
general transcription factors and transcriptional cofactors like Mediator and PC4.
The cyclical recruitment of cofactors seen before could not be recapitulated in this
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study. This might be due to the serum starvation and α-amanitin treatment that
was used to synchronize the pS2 promoter. Such precautions were not made for
the doxycycline inducible gene promoters Vβ8.1 and CMV. Therefore we have
to assume that we monitor steady state levels of the transcription cofactors on the
promoter. Recruitment of all the factors monitored seem to happen with the same
kinetic with the sole exception of PC4 that appears at a later step in PIC assembly.
The recruitment of TFIIB, TFIIH, Mediator and Pol II could not be separated from
each other. However, changes in Mediator could be resolved and will be discussed
in further details below.
4.3 VP16-dependent recruitment of MED25
In a biochemical screen for VP16 interacting proteins, MED25 could be charac-
terized as the major interaction partner of VP16 in the human Mediator complex
[Mittler et al., 2003, Yang et al., 2004]. Depletion of MED25 containing Medi-
ator complexes (A-Med) leads to a loss of VP16 specific activation in in vitro
transcription assays. Additionally, the N-terminal Mediator-binding domain of
MED25 (NTD) was shown to act dominant negatively on VP16-driven transcrip-
tion in reporter assays. It is noteworthy than no other activator tested nor basal
transcription levels were affected by overexpression of NTD [Mittler et al., 2003].
This clearly argues for an activator specific function of A-Med. Using the in-
ducible system, VP16-dependent recruitment of MED25 was demonstrated in
vivo (Fig.13). This was shown on two independent model promoters, namely the
Vβ8.1 and CMV. The two promoters vary in various aspects. On the Vβ8.1 pro-
moter, MED25 levels increased about 20 fold, which correlated with increased
levels of Pol II (Fig.13). In an immobilized template assay, VP16-dependent
binding of Mediator to the MRG5 promoter could be demonstrated to depend
on MED25 (Fig.19). This would argue that a distinct Mediator complex, A-Med
is recruited to the promoter. However, it could also be that independently of Medi-
ator free MED25 is recruited and becomes incorporated into the complex. It was
shown that free flag-MED25 can be integrated into Mediator complexes during
IP experiments to determine the minimal Mediator binding domain in MED25
[Mittler et al., 2003]. However, free MED25 could not complement for A-Med
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function in an in vitro transcription assay so far which would rather be an in-
dication that endogenous MED25 was exchanged with exogenous flag-MED25
instead.
As an unexpected finding in the ChIP experiments, MED1 was found to be present
at the Vβ8.1 promoter even before the system was turned on. Addition of doxy-
cycline did not change MED1 levels, as if no additional MED1 gets recruited
together with A-Med. Only recently have Mediator complexes been characterized
that lack MED1 [Taatjes and Tjian, 2004, Malik et al., 2005]. In an immobilized
template assay, we could demonstrate the VP16-dependent recruitment of a Me-
diator complex containing MED1. However, addition of nucleotides lead to a loss
of MED1 from the complex (Fig.20). This finding could explain why no change
in MED1 levels could be observed in the ChIP assay. A similar finding was re-
ported using p53 as an activator [Malik et al., 2005]. It looks like MED1, even
though required by nuclear hormone receptors can be omitted by activators like
VP16 and p53 [Malik et al., 2005]. In the same study, the authors even propose
that most of human mediator lacks MED1. Taken together, these findings point
towards a more dynamic model of Mediator in which Mediator can change its
subunit composition depending on the activator.
The fact that MED1 was found to be present on the Vβ8.1 promoter even before
induction of the system might be due to the structure of the promoter. Of the
Vβ8.1 promoter of the TCRβ chain a 1kb fragment was used, including upstream
and downstream sequences as well as several endogenous activator binding sites
(Ets, CREB, SP1) (Fig.15). This explanation is plausible since the basal transcrip-
tion levels from the Vβ8.1 promoter are higher than the one seen from the CMV
promoter. The CMV promoter is a minimal viral promoter with high induction
rates and low background activity, that is widely used in eucaryotic expression
plasmids. In addition to that, the TRE in the Vβ8.1 promoter is located more
distal to the transcription start site compared to the short minimal promoter se-
quence of the CMV promoter. Furthermore, the seven Tet-binding sites could be
responsible for synergistic effects that could lead to a preoccupied Vβ8.1 pro-
moter. However, this concern can be appeased, since the system is responsive to
the dominant negative effect that NTD exerts on VP16 activation. Indicating that
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VP16 dependent transcription initiation in this system is also mainly dependent
on A-Med.
4.4 The A-Med complex
Human Mediator complexes have been isolated in several laboratories in inde-
pendent lines of research using different activators or functional assays. All these
complexes, ARC/CRSP, DRIP, PC2, SMCC and TRAP turned out to represent hu-
man Mediator complexes [Blazek et al., 2005, Malik and Roeder, 2005b]. These
different complexes share a consensus set of subunits [Sato et al., 2004]. To date,
37 different subunits have been characterized in different organisms from which
22 are conserved in all eukaryotes [Bourbon et al., 2004]. The conserved subunits
most likely form the core of Mediator. However, it is unclear whether the many
human Mediator complexes are the product of the different purification strategies
or if they are functionally distinct complexes.
Mediator is know to have a modular organization and can be divided into head,
middle, tail and kinase modules. The tail module is formed by MED24, MED23
and MED16. It is likely that this three subunits form a bona fide submodule, since
Mediator complexes isolated from mouse cells in which the genes encoding either
MED24 [Ito et al., 2002b] or MED23 [Wang et al., 2001, Wang and Berk, 2002]
have been knocked out are deficient for all three subunits. This submodule has
been discussed to play a major role in integrating signals form different activa-
tors, even if they do not bind directly to any of the three subunits. For exam-
ple, nuclear hormone receptors no longer activate transcription in reporter assays
if the MED24 subunit is knocked out, even though MED1 and not MED24 is
the direct interaction partner. In contrast to this, overexpression of the NTD of
MED25 shows a dominant negative effect in reporter assay only for VP16, ac-
tivation by nuclear hormone receptors are not impaired [Mittler et al., 2003]. In
turn, activation by VP16 is impaired in the MED24 knock out cell, as well as
activation by p53 and others [Ito et al., 2002a]. It seems that activators although
bound to different Mediator subunits can transmit a signal within the complex
from their respective point of interaction to the Mediator tail domain. This the-
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ory is supported by expression profiling in yeast. This report shows that MED2
and MED18, both subunits of the tail, function downstream of the Cdk8 module
[van de Peppel et al., 2005]. Interpreting the expression profile shows that med2∆
is completely dominant over cdk8∆ of cycc∆, with no additional effects observed
when deleting the Cdk8 subunit in med2∆. Phosphorylation of MED2 was pro-
posed as mechanism for the negative regulatory pathway within Mediator. Indeed,
it was shown that MED2 can be phosphorylated in vitro [Hallberg et al., 2004]
and in vivo [van de Peppel et al., 2005] by Cdk8. Furthermore, functional an-
tagonism between the Cdk8 module and the tail (Med15, Med2, Med3), head
(Med20, Med18) and middle (Med31) could be shown by expression profiling
[van de Peppel et al., 2005]. Which is an indication that different subunits within
the same complex can have opposite roles on the same genes. Neither MED2 nor
MED3 have homologs in the mammalian Mediator and in turn, neither MED23
nor MED24 have a homologue in the yeast Mediator. Nevertheless, all of this
subunits are located in the tail region of yeast and human Mediator, respectively
and play a role in activated transcription. One might ask whether these subunits
are at least the functional homologs of each other.
It seems reasonable to propose that the transcriptionally active A-Med complex
contains the submodule formed by MED24, MED23 and MED16. Indeed, when
using the MED23 antibody in ChIP assays, a strong accumulation of MED23 on
the Vβ8.1 and CMV promoters was observed. One can think of two possible sce-
narios: 1) A large mediator complex is recruited to the promoter and gets subse-
quentially remodeled or 2) a smaller Mediator complex lacking the activating tail
module that gets recruited independently of the complex. To answer this question
a short-term ChIP kinetics was applied, resolving the first five minutes after VP16
activation (Fig.16). Even after this short time points following transcription induc-
tion it was not possible to dissect whether a complex or the different submodules
were recruited. This might be due to the limitations of ChIP experiments. In ChIP,
one always monitors the steady-state levels and not the transition-state levels that
are of transient nature. To investigate this transition-states an in vitro assay is a
more powerful tool. In an immobilized template assay a large Mediator complex
(containing Cdk8) is recruited by VP16 to the MRG5 promoter in vitro (Fig.20),
therefore one has to conclude that model 1 seems to be the more likely one.
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During open complex formation in an immobilized template assay Mediator did
change in its subunit composition (Fig.20). MED1 was one of the subunits that
was lost. This is in support with the finding that VP16 activation does not lead
to an accumulation of MED1 on the Vβ8.1 promoter nor on the CMV promoter
seen in the ChIP assays. In recent publications, a sub-fraction of the CRSP com-
plex (CRSP/Med2) [Taatjes and Tjian, 2004] could be purified missing MED1
and for p53 activated transcription a loss of MED1 could be demonstrated in vitro
[Malik et al., 2005].
MED1 containing complexes are involved in activated transcription through nu-
clear hormone receptors. Knock out of MED1 leads to the loss of activation by nu-
clear hormone receptors such as TR and ER but not by VP16. Mediator complexes
purified by MED1 are highly enriched in Pol II and interestingly, these complexes
also contain MED25 [Xiaoting Zhang, 2005]. A question that arises is whether
MED25 is found in all active Mediator complexes. There are many arguments
against this hypothesis, among them that NTD only acts dominant negatively on
VP16 but not on ER for example. Another argument against a general function
of MED25 in transcription is that MED25 is only associated with a fraction of
Mediator. However, the model gets some support from the ChIP result that shows
VP16 dependent recruitment of MED23 in vivo, that forms the tail of Mediator
which was shown to be crucial for all activators [Ito et al., 2002b]. Since the lo-
calization of MED25 within the complex is unknown it would be interesting to
know whether MED25 contacts or influences the tail module. With regard to the
low resolution EM structures for VP16 bound Mediator, it would be reasonable
to predict the localization of MED25 in the head module of Mediator. However,
given the structural flexibility of Mediator shown in these EM structures the pres-
ence of MED25 could introduce a Mediator conformation that allows for binding
of the activating tail module. Since only VP16 makes direct contact to MED25
this could explain why only defects for VP16 activation could be observed when
overexpressing NTD.
The main question remains how A-Med differs from other Mediator forms. One
explanation might come from the observation that affinity purified Mediator with
antibodies directed either against MED25 or MED15 copurify different accessory
proteins as was shown by masspectromety [Stuehler Thomas, 2005]. It is striking
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that in the MED25 IP many proteins involved in histone modification as well as
RNA processing were copurified. These proteins were absent in the MED15 IP.
In this light, it might be possible that A-Med establishes a link between the basal
transcription machinery and histone modification as well as RNA processing.
4.5 The Cdk8 kinase module
Cdk8 is one of the best studied Mediator subunit, and several different models
have been proposed for the mechanism of Cdk8 function. In mammalian cells,
Cdk8 was shown to phosphorylate the CTD of the largest subunit of Pol II and
thus activates transcription. Additionally, Cdk8 has a negative regulatory func-
tion by phosphorylation of the Cyclin H subunit of the general transcription factor
TFIIH. This phosphorylation represses both the ability of TFIIH to activate tran-
scription and its CTD kinase activity[Akoulitchev et al., 2000]. Cdk8 has also
been implied in regulating the turnover of the Notch enhancer complex at tar-
get genes [Fryer, 2004]. Mastermind binds directly to Cdk8 and recruits it to
the Notch receptor intracellular domain (ICD). Cdk8 promotes phosphorylation
of Notch ICD that leads to PEST-dependent degradation and therefore to nega-
tive transcription regulation. A similar model was proposed in yeast, where Cdk8
(Srb10) inhibits filamentous growth in cells growing in rich medium by phos-
phorylation of Ste12 and thus decreasing its stability [Nelson C, 2003]. Positive
roles for Cdk8 could be shown in yeast, where Cdk8 (Srb10) phosphorylates Sip4
during growth in non glucose media [Vincent et al., 2001]. Additionally, Cdk8
(Srb10) and Cdk7 (Kin28) were shown in yeast to have overlapping roles in pro-
moting ATP-dependent dissociation of the preinitiation complex into the scaffold
complex[Liu et al., 2004]. It was shown in mammalian cells as well as in S.pombe
that Mediator binding to either Pol II CTD or to the kinase module is mutually
exclusive [Naar, 1998, Spahr et al., 2000]. Studies of mammalian transcription
showed that for some genes, Cdk8 is associated with inactive transcription com-
plexes that have to be activated [Pavri et al., 2005]. PARP-1 was proposed to func-
tion as a specificity factor regulating the retinoic acid-induced switch of Mediator
from the inactive to the active state in RAR-dependent transcription. However in
a controversial study on the Egr1 promoter, no transition from inactive to active
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Mediator was observed and Cdk8 localizes with the initiation complex of active
genes [Wang et al., 2005].
In this work, the loss of the Cdk8 module could be shown in vivo (Fig.14) as
well as in vitro (Fig.20). In ChIP experiments a loss of Cdk8 and MED13 was
observed on the Vβ8.1 promoter after VP16 activation (Fig.14). The loss of the
Cdk8 module upon VP16 activation in vivo is in line with the idea of derepres-
sion of Mediator function and follows most likely a similar mechanism as seen
in vitro. This seems to be a fast process, Cdk8 was lost on the relatively weak
Vβ8.1 promoter within the first 5 minutes after induction, on the strong CMV
promoter it is not even detectable. The controversy of the in vivo results reported
might to some extend account to what promoter was used for these investiga-
tions. In immobilized template assays Mediator, Pol II and TFIIH are recruited
in a VP16 dependent manner to the promoter. Depletion of MED25 from a nu-
clear extract (∆MED25) lead to a loss of VP16-dependent Mediator binding. This
again underlines the crucial function of MED25 in VP16 activated transcription.
In the absence of nucleotides, the recruited Mediator complex contained the Cdk8
module as well as all of the tested subunits; MED1, MED7 and MED25. In the
presence of nucleotides however, a loss of Cdk8 and MED1 was observed. The
other two Mediator subunits tested were less affected. The remaining of Mediator
on the promoter is in line with studies in yeast that show the formation of a scaf-
fold complex after transcription initiation that facilitates transcription reinitiation.
Addition of ATP or a nucleotide mix renders the assembled preinitiation complex
into the open complex form and Pol II can start transcribing. Therefore the ob-
served loss of Pol II on the immobilized template is expected. In our analysis, the
loss of Cdk8 and Pol II is dependent on a kinase, since the kinase inhibitor H8 is
able to completely block both the loss of Cdk8 and Pol II (Fig.21). Whereas most
of the phosphorylated proteins remained on the template, only few proteins were
recovered from the supernatant. The most prominent one forms a double band at
around 50 kDa that could be Cdk8. The loss of MED1 however is not blocked by
H8, and is therefore probably not phosphorylation dependent.
Previously, A-Med was defined as a MED25 containing Mediator complex that is
crucial for VP16-driven transcription activation in vivo and in vitro. Summarizing
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these results here, a refined definition can be made. Active A-Med does not con-
tain the Cdk8 module as was shown in vivo and in vitro. The ChIP experiments
implied a fast dissociation of the kinase, only on the preactivated Vβ8.1 with its
prebound Mediator complex a dissociation of Cdk8 could be shown but not on the
CMV promoter. The dissociation of Cdk8 together with Pol II is dependent on
nucleotides and can be blocked by the kinase inhibitor H8. Phosphorylation alone
leads to open complex formation and the dissociation of Pol II but not of Cdk8
from Mediator.
4.6 VP16 effects on chromatin
VP16 binding let to the recruitment of the two histone acetyltransferases CBP and
GCN5, the catalytic subunit of the human STAGA complex (Fig.17). This was
observed on both, the Vβ8.1 and the CMV promoter. Surprisingly only moderate
hyperacetylation of either histone H3K9 or histone H4 on both promoters as well
as in the coding region was seen. One explanation might be that nucleosomes
are already modified in the non activated state on the EBV reporters. These EBV
vectors are basically nothing else than mini EBV episomes and it was shown for
wild type as well as exogenous EBV episomes that their histones are modified
[Chau CM. and Lieberman PM., 2004, Zhou J., 2005] [Chau CM. and Lieberman
PM., 2004, Zhou J., 2005]. These modifications include histone acetylation and
methylation and were shown to spread several kilo bases up- and downstream of
the oriP region. The only region having less modifications on the episomes is
the oriP region, which seems be looser packed by histones for better accessibility
during replication [Chau CM. and Lieberman PM., 2004, Zhou J., 2005]. For
a role of CBP argues the direct interaction with MED25 as was shown in an in
vitro GST-pull down assay (Fig.25). This interaction with the ACID domain of
MED25 is apparently possible through both the N- and C-terminal parts of CBP.
Both VP16 and CBP interact through the ACID domain with MED25. It would
be interesting to see whether this is a concerted interaction between the three
partners. The H1 and H2 region of VP16 function through distinct pathways.
The H1 region can function through Mediator and general transcription factors
whereas the H2 requires CBP [Ikeda et al., 2002]. A second explanation for the
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moderate hyperacetylation observed might be due to enhanced levels of HDACs
on the promoter. Preliminary data suggest enhanced levels of HDAC1 and 2 on
the Vβ promoter. If this would be the case, the net effect could result in only
moderate hyperacetylation of either histone H3K9 or histone H4.
Certain histone methylation marker are correlated to actively transcribed genes
[Jenuwein and Allis, 2001, Kouzarides, 2002]. These modifications are namely,
histone H3K4 and histone H3K79, each existing in a mono-, di- or trimethylated
form. Like the antibodies directed against acetylated histones, the histone H3K4
trimethylation did only moderately change upon VP16 activation. Again, this
specific modification is already found in wild type EBV episomes to spread over
a large distance [Chau CM. and Lieberman PM., 2004]. However the dimethyl
modification of histone H3K79 showed a strong response to VP16 activation.
The only known histone methyl transferase (HMTase) known responsible for this
modification is Dot1L. Interestingly, Dot1L was among the peptides that cop-
precipitated specifically in a MED25 IP. Unfortunately, Dot1L escaped a direct
identification in western blot analysis due to the lack of sensitive antibodies. To
date, there is one publication that links Dot1L to leukemogenesis via MLL-AF10
[Okada, 2005]. However how Dot1L is targeted to active promoters is still un-
known. An association with Mediator would nicely explain the correlation of
histone H3K79 methylation with active genes.
4.7 A link of transcription to RNA processing via Mediator?
Affinity purified A-Med with an antibody directed against MED25 coprecipi-
tates different accessory proteins as was shown by mass spectrometry [Stühler
T., 2006]. Some of these proteins are involved in RNA processing. Namely all
the subunits of the cleavage and polyadenylation complex (CPSF) and the cleav-
age stimulatory factor (CstF) were copurified in the MED25 IP. These data have
not yet been confirmed by additional biochemical data. However in ChIP experi-
ments members of both complexes could be detected at the model promoters after
VP16 activation. Strikingly, CPSF1 and CstF64 were the only two proteins mon-
itored, besides PC4, that arrived relatively late at the promoters. They were only
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detectable 5 to 30 minutes after activation, whereas the other components of the
general transcription machinery arrived within the first 5 minutes.
In the last years, numerous studies have indicated that transcription of mRNA pre-
cursors and subsequent processing (i.e. capping, splicing and polyadenylation)
are closely connected and many reports support the idea that the CTD of Pol II
coordinates these processing steps (reviewed in [Hirose, 2000, Proudfoot, 2002,
Zorio, 2004]). Polyadenylation of mRNA precursors is a two-step reaction involv-
ing endonucleolytic cleavage of the pre-mRNA and synthesis of the poly(A) tail.
In mammalian cells, the component of the polyadenylation complex include CPSF
which recognizes the AAUAAA signal; CstF which bind to a GU-rich sequence
downstream of the cleavage site and two cleavage factors CF I and CF II as well
as poly(A) polymerase (PAP). In a yeast two hybrid screen CstF-64 was shown to
interact with PC4 [Calvo O., 2001]. The interaction of this two proteins proofed
to be evolutionarily conserved between yeast and man and providing evidence
that this is important for efficient transcription elongation. Furthermore, Sub1
and Rna15, the yeast homologs of PC4 and CstF-64, respectively were shown to
be recruited to promoters and are present along the length of several yeast genes
[Calvo O., 2005].
Of interest here in this study is not only the fact that members of the 3‘ end for-
mation complexes were found at a mammalian promoter but also the fact that
they are recruited timely correlated with PC4. This finding provides evidence for
a conserved mode of action of PC4 and CstF-64 between yeast and man. It is
noteworthy that only after the recruitment of PC4 and CstF-64 increased levels of
luciferase mRNA could be detected (Fig.18). Of additional interest is the circum-
stance that CPSF and CstF are coprecipitated by A-Med. This might indicate a
role for A-Med not only in transcription initiation but also in efficient elongation
or RNA processing by recruitment of CPSF and CstF.
4.8 Subcellular localization of MED25
MED25 is a newly characterized Mediator subunit that contains an N-terminal
Mediator binding domain with homologies to the Von-Willebrand factor A domain
99
4.8 Subcellular localization of MED25 4 DISCUSSION
(VWA) and a novel C-terminal activator interaction domain (ACID). Only one
other protein is known to carry an ACID domain, PTOV-1 (prostate tumor over-
expressed protein 1). PTOV-1 consists of two repeated ACID domains (Fig.24A).
The gene encoding PTOV-1 lies just adjacent to the MED25 gene on chromosome
19q13.33. PTOV-1 was not only shown to be overexpressed in prostate tumor cells
but was also shown to shuttle between the cytoplasm and the nucleus in a cell-
cycle dependent manner [Santamaria A., 2003]. Flotillin-1, a major lipid raft pro-
tein, gets translocated to the nucleus together with PTOV-1[Santamaria A., 2005].
Both proteins have a mitogenic activity and seem to act together. Interestingly,
deletion of PTOV-1 inhibits cell proliferation, whereas overexpression leads to
strongly induced cell proliferation [Santamaria A., 2005].
As mentioned, PTOV-1 consists of two repeated ACID domains, that we char-
acterized as an activator binding domain [Mittler et al., 2003]. Overexpression
of PTOV-1 brings additional ACID domains into a cell that could compete with
MED25 for activators to bind. This competition could impair cellcycle regulation
and lead to the increased cell proliferation that is observed.
Figure 30: Sequence alignment of human ACID domains from MED25 (ACID1)
or PTOV-1 (ACID2.1 and ACID2.2). Amino acids 20 to 29 of the MED25 ACID
domain are partially deleted in the PTOV-1 ACID domains. Conserved regions
are boxed in gray.
It seems possible that the ACID domain is not only a novel protein-protein interac-
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tion domain but is also responsible for the cell-cycle dependent nuclear transloca-
tion of PTOV-1. To test whether MED25 also changes its cellular distribution, nu-
clear extracts of synchronized cells were monitored in Western blots for MED25
levels. However no change in MED25 protein levels were observed during the
cell cycle (Fig.24B). A predominant nuclear localization was observed using con-
focal immunofluorescence microscopy where the localization of overexpressed
flag-MED25 was analyzed (Fig.23). Despite the homology of the ACID domains,
MED25 does not seem to have a cytoplasmic function like PTOV-1 and it local-
izes to the nucleus at all times. The reason for this might be in the ACID domain
itself. There is a stretch of 10 amino acids in the ACID domain of MED25 that is
partially deleted in the ACID domains of PTOV-1 (Fig.30). This region is not pre-
dicted to form strand or helical secondary structure but might nevertheless account
for a specific function. Even though preliminary interaction studies indicate bind-
ing of VP16 to all three ACID domains, the binding to PTOV-1 derived domains
seems to be less specific (data not shown). An other reason for the different behav-
ior of MED25 and PTOV-1 might be the duplication of the ACID domain. This
hypothesis could be tested by generating a MED25 mutant carrying a duplicated
ACID domain or the PTOV-1 derived ACID domains. In such an experiment it
would be interesting to see whether the localization or the specificity of the mutant
MED25 is changed.
To conclude, the ACID domain of MED25 is not able to confer cell-cycle de-
pendent translocation of MED25 from the cytoplasm to the nucleus. However
the localization of MED25 is nuclear which might be due to the ACID domain.
Whether the cycling of the PTOV-1 protein depends on slight differences within
the ACID domain or in the duplication of the ACID domain remains unclear. An
intriguing model would be that the ACID domain is responsible for the transport
to the nucleus, where MED25, in contrast to PTOV-1, gets retained by its ability
to bind to Mediator.
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4.9 Conclusion
To summarize the emerging picture of VP16 activation through A-Med function
the following working model can be drawn. VP16-dependent activation is medi-
ated by A-Med, a complex lacking the Cdk8 module as well as the MED1 sub-
unit. However A-Med contains the MED16/MED23/MED24 tail module. From
in vitro data we can draw the conclusion that a large Mediator, probably TRAP or
a TRAP-like complex gets recruited by VP16. The question remains whether the
MED16/MED23/MED24 module is present in the recruited complex or if they get
integrated separately. During open complex formation MED1 and the Cdk8 mod-
ule are lost from the complex in a phosphorylation dependent manner to form an
active A-Med complex. In this, Mediator shows not only a conformational flex-
ibility but also a dynamic nature of subunit composition. In which probably its
capacity as a processor of diverse signals that act on him in the form of activators,
repressors and coactivators lies.
In addition A-Med can act as a central control panel and integrate several addi-
tional cofactors into the transcription complex before Pol II transcription finally
starts. CBP can be directly recruited by Mediator through the ACID domain of
MED25. Additionally, A-Med can target Dot1L the histone methyltransferase
responsible for H3K79 methylation that is correlated to all actively transcribed
gens. Finally, A-Med binds to the polyadenylation factors CPSF and CstF and
targets these factors to the promoter where they get loaded onto the CTD of Pol II.
Taken together, A-Med seems to integrate activities used for histone modification,
transcription, polyadenylation and termination.
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4.9 Conclusion 4 DISCUSSION
Figure 31: Model of VP16 activation and A-Med function. VP16 recruits A-Med
through the ACID domain of MED25. A-Med contains the activating tail mod-
ule formed by MED16/MED23/MED24 but looses MED1 and the Cdk8 module
during open complex formation. The loss of the Cdk8 module phosphorylation
dependent. In addition, A-Med can interact with further transcription coactivators
like CBP, Dot1L, CPSF and CstF. Together A-Med forms a scaffold that com-
bines activities required for histone modification, transcription initiation and RNA
polyadenylation.
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